US20030216548A1 - Sp110, a polypeptide component of the nuclear body - Google Patents
Sp110, a polypeptide component of the nuclear body Download PDFInfo
- Publication number
- US20030216548A1 US20030216548A1 US10/333,227 US33322703A US2003216548A1 US 20030216548 A1 US20030216548 A1 US 20030216548A1 US 33322703 A US33322703 A US 33322703A US 2003216548 A1 US2003216548 A1 US 2003216548A1
- Authority
- US
- United States
- Prior art keywords
- polypeptide
- seq
- amino acids
- domain
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 135
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 125
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 claims abstract description 62
- 108020004414 DNA Proteins 0.000 claims abstract description 47
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims abstract description 33
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims abstract description 33
- 238000012216 screening Methods 0.000 claims abstract description 23
- 150000001413 amino acids Chemical class 0.000 claims description 81
- 230000014509 gene expression Effects 0.000 claims description 78
- 230000027455 binding Effects 0.000 claims description 55
- 150000001875 compounds Chemical class 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 44
- 125000003729 nucleotide group Chemical group 0.000 claims description 44
- 239000012488 sample solution Substances 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
- 108700008625 Reporter Genes Proteins 0.000 claims description 33
- 239000004576 sand Substances 0.000 claims description 33
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 29
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 29
- 108050009021 Bromodomains Proteins 0.000 claims description 29
- 102000001805 Bromodomains Human genes 0.000 claims description 29
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 29
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 238000006471 dimerization reaction Methods 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 18
- 102000001420 Homeobox domains Human genes 0.000 claims description 16
- 108050009606 Homeobox domains Proteins 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 16
- 239000000539 dimer Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 8
- 239000000833 heterodimer Substances 0.000 claims description 7
- 102000003939 Membrane transport proteins Human genes 0.000 claims description 5
- 108090000301 Membrane transport proteins Proteins 0.000 claims description 5
- 230000009061 membrane transport Effects 0.000 claims description 5
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000004393 prognosis Methods 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 104
- 108090000623 proteins and genes Proteins 0.000 abstract description 82
- 239000002299 complementary DNA Substances 0.000 abstract description 25
- 238000013518 transcription Methods 0.000 abstract description 17
- 230000035897 transcription Effects 0.000 abstract description 17
- 230000006870 function Effects 0.000 abstract description 13
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 13
- 239000012190 activator Substances 0.000 abstract description 12
- 210000000265 leukocyte Anatomy 0.000 abstract description 11
- 102000004127 Cytokines Human genes 0.000 abstract description 8
- 108090000695 Cytokines Proteins 0.000 abstract description 8
- 210000002889 endothelial cell Anatomy 0.000 abstract description 3
- 238000012512 characterization method Methods 0.000 abstract description 2
- 210000002064 heart cell Anatomy 0.000 abstract description 2
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 238000007374 clinical diagnostic method Methods 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 102000023984 PPAR alpha Human genes 0.000 description 76
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 76
- 235000001014 amino acid Nutrition 0.000 description 67
- 229940024606 amino acid Drugs 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 49
- 230000003993 interaction Effects 0.000 description 41
- 230000000694 effects Effects 0.000 description 37
- 239000012634 fragment Substances 0.000 description 27
- 230000001404 mediated effect Effects 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 17
- 241000701161 unidentified adenovirus Species 0.000 description 17
- 125000000539 amino acid group Chemical group 0.000 description 16
- 108020001507 fusion proteins Proteins 0.000 description 16
- 102000037865 fusion proteins Human genes 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 230000004913 activation Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000003647 oxidation Effects 0.000 description 13
- 238000007254 oxidation reaction Methods 0.000 description 13
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 12
- 238000003119 immunoblot Methods 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 108020004635 Complementary DNA Proteins 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 108091027981 Response element Proteins 0.000 description 8
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 7
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000003702 retinoic acid receptors Human genes 0.000 description 6
- 108090000064 retinoic acid receptors Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 5
- 101000701625 Homo sapiens Sp110 nuclear body protein Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108010016731 PPAR gamma Proteins 0.000 description 5
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 5
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- -1 e.g. Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 102000048200 human Sp110 Human genes 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- 108091008726 retinoic acid receptors α Proteins 0.000 description 5
- 230000010740 Hormone Receptor Interactions Effects 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 108010089430 Phosphoproteins Proteins 0.000 description 4
- 102000007982 Phosphoproteins Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000003159 mammalian two-hybrid assay Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102100038495 Bile acid receptor Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 101710160287 Heterochromatin protein 1 Proteins 0.000 description 3
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006690 co-activation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000012317 liver biopsy Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 108010071511 transcriptional intermediary factor 1 Proteins 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 2
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 2
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- 101710149642 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100024590 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- 101710192017 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 101000788191 Staphylococcus aureus Uncharacterized 12.4 kDa protein Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000001403 relative X-ray reflectometry Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 108010040163 CREB-Binding Protein Proteins 0.000 description 1
- 102100021975 CREB-binding protein Human genes 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001046967 Homo sapiens Histone acetyltransferase KAT2A Proteins 0.000 description 1
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 1
- 101000701614 Homo sapiens Nuclear autoantigen Sp-100 Proteins 0.000 description 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 1
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 229940123486 Hormone receptor agonist Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 1
- 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710118310 Nuclear autoantigen Sp-100 Proteins 0.000 description 1
- 102100030436 Nuclear autoantigen Sp-100 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 description 1
- 102100025067 Potassium voltage-gated channel subfamily H member 4 Human genes 0.000 description 1
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101150047013 Sp110 gene Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- RJUXXNSHJWNJBM-UHFFFAOYSA-N [Cl-].[Cs+].[N-]=C=S.NC([NH3+])=N Chemical compound [Cl-].[Cs+].[N-]=C=S.NC([NH3+])=N RJUXXNSHJWNJBM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000011490 co-immunoprecipitation assay Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- IPCSVZSSVZVIGE-VPMSBSONSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCC[14C](O)=O IPCSVZSSVZVIGE-VPMSBSONSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000000698 hormone receptor stimulating agent Substances 0.000 description 1
- 102000044266 human Sp100 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000018252 regulation of lipid storage Effects 0.000 description 1
- 230000031070 response to heat Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Definitions
- This invention relates to molecular biology, biochemistry, cell biology, medicine and medical diagnostics.
- the nuclear body is a multiprotein complex located within the nuclei of cells.
- the nuclear body is also known as nuclear domain 10, PML oncogenic domain, and the Kr body.
- Immunohistochemical staining typically indicates 5-30 nuclear bodies within a nucleus.
- the nuclear bodies appear as discrete, punctate regions.
- the number of nuclear bodies in the cell, and the intensity of antibody staining of these structures increase in response to heat shock and viral infection, as well as following exposure to interferons and heavy metals (Ascoli et al., J. Cell Biol. 112:785-795, 1991).
- the nuclear body appears to be involved in the regulation of gene transcription.
- Nascent RNA polymerase II transcripts have been found within the nuclear body (LaMorte et al., Proc. Natl. Acad. Sci. USA 95:4991-4996, 1998), and the nuclear body is a preferred site for transcription of viral genes (Ishov et al., J. Cell. Biol. 138:5-16, 1997).
- Promyelocytic leukemia (PML) protein is a component of the nuclear body.
- PML protein is involved in several cellular processes. For example, PML protein regulates cell growth (Wang, et al., Science 279:1547-1551, 1998) and may mediate apoptosis (Wang, et al., Nature Genetics 20:266-272, 1998; Quumble et al., Nature Genetics 10:259-265, 1998). PML protein also recruits cAMP response element-binding protein (the CREB-binding protein or CBP) to the nuclear body and functions as a potent nuclear hormone receptor co-activator (Doucas et al., Proc. Natl. Acad. Sci. USA 96:2627-2632, 1999).
- CBP cAMP response element-binding protein
- the nuclear body is a target of autoantibodies in the sera of patients who have primary biliary cirrhosis (P BC), an autoimmune disease (Hodges et al., Am. J. Hum. Genet. 63:297-304, 199&; Melnick et al., Blood 93: 3167-3215, 1999; Stemsdorf et al., Immunobiology 198:307-331, 1997).
- PBC patients carry autoantibodies directed against Sp100 (Speckled 100 kDa), a polypeptide component of the nuclear body (Szostecki et al., J. Immunol. 145:4338-4347, 1990).
- Sp100b and Sp100-HMG Two splice variants of Sp100, designated Sp100b and Sp100-HMG, have also been found (Dent et al., Blood 88:1423-1436, 1996; Seeler et al. Proc. Natl. Acad. Sci. USA. 95:7316-7321, 1998; Lehining et al., Proc. Natl. Acad. Sci. USA 95:7322-7326, 1998). These proteins interact with members of the heterochromatin protein 1 (HP1) family of non-histone chromosomal proteins. When bound to a promoter, the Sp100 proteins and HP1 behave as transcriptional repressors in transfected cells.
- HP1 heterochromatin protein 1
- Sp140 leukocyte-specific component of the nuclear body designated Sp140 (Bloch et al., J. Biol. Chem. 46:29198-29204, 1996).
- the N-terminal portion of Sp140 exhibits sequence homology with the N-terminal segments of the Sp100 proteins.
- the middle region of Sp140 contains a “SAND” domain (Gibson et al., Trends Biochem. Sci. 23:242-244, 1998), and the C-terminal portion of Sp140 contains a plant homeobox domain and a bromodomain.
- Sp110 is a component of the nuclear body, is expressed in leukocytes, and is also expressed in other types of cells, including endothelial cells, smooth muscle cells, liver cells and heart cells, after contact with, cytokines, including tumor necrosis factor, interleukin 1, and interferons.
- Other discoveries include the following: Sp140 recruits Sp110 to the nuclear body, Sp110 functions as an activator of gene transcription, and Sp110 serves as a nuclear hormone receptor co-activator.
- the invention features an isolated DNA containing a nucleotide sequence whose complement hybridizes under stringent hybridization conditions to a DNA molecule whose nucleotide sequence consists of nucleotides 405 to 797 of the Sp110 cDNA (SEQ ID NO:1).
- the isolated DNA also includes at least one of the following: a nucleotide sequence encoding a domain having at least 80% sequence identity with amino acids 6-109 (Sp100-like domain) of the Sp110 polypeptide (SEQ ID NO:2); a domain having at least 80% sequence identity with amino acids 454-532 of SEQ ID NO:2 (SAND domain); a domain having at least 80% sequence identity with amino acids 537-577 of SEQ ID NO:2 (plant homeobox domain); and a domain having at least 80% sequence identity with amino acids 606-674 of SEQ ID NO:2 (bromodomain).
- the DNA hybridizes as described above and includes a nucleotide sequence encoding at least one of the following: amino acids 6-109 of SEQ ID NO:2 (Sp100-like domain) or amino acids 6-109 of SEQ ID NO:2 with one or more, e.g., 5, 10, 15 or 20 conservative amino acid substitutions therein; amino acids 454-532 of SEQ ID NO:2 (SAND domain) or amino acids 454-532 of SEQ ID NO:2 with one or more, e.g., 5, 10, 15 or 20, conservative amino acid substitutions therein; amino acids 537-577 of SEQ ID NO:2 (plant homeobox domain) or amino acids 537-577 of SEQ ID NO:2 with one or more, e.g., 5, 10, 15 or 20, conservative amino acid substitutions therein; and amino acids 606-674 of SEQ ID NO:2 (bromodomain) or amino acids 606-674 of SEQ ID NO:2 with one or more, 5, 10, 15 or 20, conservative amino acid substitutions therein; and amino acids 606-674
- the isolated DNA hybridizes as described above, and also includes a nucleotide sequence encoding all of the following: amino acids 6-109 of SEQ ID NO:2 (Sp100-like domain) or amino acids 6-109 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; amino acids 454-532 of SEQ ID NO:2 (SAND domain) or amino acids 454-532 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; amino acids 537-577 of SEQ ID NO:2 (plant homeobox domain) or amino acids 537-577 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; and amino acids 606-674 of SEQ ID NO:2 (bromodomain) or amino acids 606-674 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein.
- the isolated DNA contains a nucleotide sequence that encodes a polypeptide whose amino acid sequence is the sequence set forth as SEQ ID NO:2 or the sequence set forth as SEQ ID NO:2, with one or more, e.g., 5, 10, 15 or 20 conservative amino acid substitutions therein.
- the isolated DNA hybridizes as described above and also includes a nucleotide sequence encoding an Sp110 inhibitor polypeptide containing: amino acids 6-109 of SEQ ID NO:2 (Sp100-like domain) or amino acids 6-109 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; amino acids 537-577 of SEQ ID NO:2 (plant homeobox domain) or amino acids 537-577 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; and amino acids 606-674 of SEQ ID NO:2 (bromodomain) or amino acids 606-674 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; wherein the polypeptide does not contain a SAND domain.
- an Sp110 inhibitor polypeptide containing: amino acids 6-109 of SEQ ID NO:2 (Sp100-like domain) or amino acids 6-109 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; amino acids 537-577 of SEQ ID NO:2 (plant home
- the isolated DNA contains a nucleotide sequence (Sp110 splice variant) that encodes the amino acid sequence set forth as SEQ ID NO:5, or the sequence set forth as SEQ ID NO:5 with one or more, e.g., 5, 10, 15 or 20, conservative amino acid substitutions therein.
- a nucleotide sequence Sp110 splice variant that encodes the amino acid sequence set forth as SEQ ID NO:5, or the sequence set forth as SEQ ID NO:5 with one or more, e.g., 5, 10, 15 or 20, conservative amino acid substitutions therein.
- the invention also features a vector containing any of the DNAs described above, and a host cell containing the vector.
- the DNA can be operably linked to one or more expression control sequences.
- the invention also features a substantially pure polypeptide encoded by any of the DNAs described above.
- the invention includes a substantially pure polypeptide (an inhibitor of Sp110 activity) containing an Sp110 Sp100-like domain, an Sp110 SAND domain, an Sp110 plant homeobox domain, and an Sp110 bromodomain, wherein the sequence of amino acids 110 to 453 of SEQ ID NO:2 is not present.
- this polypeptide includes a membrane transport moiety, i.e., a moiety that allows the polypeptide to enter a cell.
- Exemplary membrane transport moieties are an internalization peptide sequence derived from Antennapedia and an HIV tat peptide.
- the invention also features antibodies that bind specifically to the Sp110 polypeptide.
- the antibodies can be labeled.
- the invention also features a screening method for identifying a compound that inhibits Sp110 dimerization.
- the method which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound; and detecting a decrease in Sp110 dimerization in the presence of the candidate compound, as compared to Sp110 dimerization in the absence of the candidate compound.
- the invention also features a screening method for identifying a compound that enhances or promotes Sp110 dimerization.
- the method which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound; and detecting an increase in Sp110 dimerization in the presence of the candidate compound, as compared to Sp110 dimerization in the absence of the candidate compound.
- the invention also features a screening method for identifying a polypeptide that dimerizes with Sp110 to form an inactive heterodimer.
- the method includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate polypeptide, thereby forming a test mixture; providing a gene expression system comprising a reporter gene operably linked to an Sp110-responsive expression control sequence; contacting the test mixture with the gene expression system; and detecting a decrease in reporter gene expression level in the presence of the test mixture, as compared to gene expression level in the presence of the Sp110 polypeptide sample solution.
- the gene expression system can be in a living cell, e.g., a transformed host cell. Alternatively, the gene expression system can be in vitro, i.e., acellular.
- the invention also features a screening method for identifying a polypeptide that dimerizes with Sp110 to form a constitutively active or hyperactive heterodimer.
- the method includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate polypeptide, thereby forming a test mixture; providing a gene expression system comprising a reporter gene operably linked to an Sp110-responsive expression control sequence; contacting the test mixture with the gene expression system (which can be cellular or acellular); and detecting a constitutive activity or an increase in reporter gene expression level in the presence of the test mixture, as compared to gene expression level in the presence of the Sp110 polypeptide sample solution.
- the invention also features a screening method for identifying a compound or polypeptide that inhibits Sp110 binding to a nuclear hormone receptor.
- the method which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound; adding to the sample solution a nuclear hormone receptor; and detecting a decrease in Sp110 binding to the nuclear hormone receptor in the presence of the candidate compound, as compared to Sp110 binding to the nuclear hormone receptor in the absence of the candidate compound.
- the invention also features a screening method for identifying a compound or polypeptide that enhances Sp110 binding to a nuclear hormone receptor.
- the method which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound; adding to the sample solution a nuclear hormone receptor; and detecting an increase in Sp110 binding to the nuclear hormone receptor in the presence of the candidate compound, as compared to Sp110 binding to the nuclear hormone receptor in the absence of the candidate compound.
- the invention also features a screening method for identifying a compound or polypeptide that inhibits the binding of an Sp110 dimer to an Sp110-binding nucleotide sequence.
- the method which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound or polypeptide; adding to the sample solution an Sp110-binding nucleotide sequence; and detecting a decrease in Sp110 binding to the Sp110-binding nucleotide sequence in the presence of the candidate compound, as compared to Sp110 binding to the Sp110-binding nucleotide sequence in the absence of the candidate compound.
- the invention also features a screening method for identifying a compound or polypeptide that enhances or promotes the binding of an Sp110 dimer to an Sp110-binding nucleotide sequence.
- the method which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound or polypeptide; adding to the sample solution an Sp110-binding nucleotide sequence; and detecting an increase in Sp110 binding to the Sp110-binding nucleotide sequence in the presence of the candidate compound, as compared to Sp110 binding to the Sp110-binding nucleotide sequence in the absence of the candidate compound.
- the invention also features a method for diagnosing primary biliary cirrhosis (PBC) in a human patient.
- the method includes: providing a substantially pure Sp110 polypeptide; providing a serum sample from the patient; contacting Sp110 polypeptide with the serum sample; and detecting specific binding of an antibody in the serum with the Sp110 polypeptide as an indication of PBC.
- FIG. 1 is the nucleotide sequence of a full-length, human Sp110 cDNA (SEQ ID NO:1)
- FIG. 2 is a comparison of the deduced amino acid sequences of Sp110 (SEQ ID NO:2) and Sp140 (SEQ ID NO:3). Shaded portions of the sequences indicate the Sp100-like domain, the SAND domain, the plant homeobox domain (PHD), and the bromodomain. conserveed cysteine/histidine residues within the PHD are marked with asterisks.
- a dashed box encloses a predicted nuclear localization sequence, and a solid box encloses the LXXLL-type nuclear hormone receptor interaction domain.
- the sequence of the interferon-inducible protein nuclear phosphoprotein 72 begins at amino acid-241 (met) and ends at amino acid 605 (leu), which are indicated by arrows.
- FIG. 3 is the nucleotide sequence of the full-length, human Sp110 cDNA (SEQ ID NO:1) and the deduced amino acid sequence (reading frame c) of the Sp110 polypeptide (SEQ ID NO:2).
- FIG. 4 is the nucleotide sequence of a human Sp110 splice variant cDNA (Sp110b) (SEQ ID NO:4) and the deduced amino acid sequence (reading frame c) of the Sp110b polypeptide (SEQ ID NO:5).
- FIG. 5 is a schematic diagram comparing the domain structures of human Sp110, Sp140 and Sp100b. Also shown is the percent identity of the Sp110 domains, as compared to the corresponding domains in Sp140 and Sp100b.
- the full-length, naturally-occurring, human Sp110 polypeptide includes an, Sp110-like domain (amino acids 6-109 of SEQ ID NO:2), a SAND domain (amino acids 454-532 of SEQ ID NO:2), a plant homeobox domain (PHD) (amino acids 537-577 of SEQ ID NO:2), and a bromodomain (amino acids 606-674 of SEQ ID NO:2).
- the full-length Sp110 functions as an activator of gene transcription.
- Sp110 also functions as a nuclear hormone receptor co-activator.
- Some embodiments of the invention include all of the domains in a single Sp110 polypeptide. In other embodiments, however, one or more of the domains is modified or absent.
- the Sp100-like domain in the N-terminal portion of Sp110 has a potential helical motif, which can mediate homodimerization. (Seeler et al., Proc. Natl. Acad. Sci. USA 95:7316-7321, 1998). It is predicted that the Sp100-like domain in Sp110 functions in protein binding interactions, e.g., dimerization, with Sp140 or Sp100 to form a heterodimer, or dimerization with a second Sp110 polypeptide to form a homodimer.
- a polypeptide that contains an Sp110 Sp100-like domain (or derivative thereof), but does not contain an activating domain can be used in a cell to form inactive dimers comprising Sp140, Sp100 or Sp110.
- inactive dimers reduces the availability of endogenous Sp140, Sp100 or Sp110 monomers for formation of active (transcription-activating or transcription-inhibiting) dimers, thereby reducing Sp140, Sp100, or Sp110 activity in the cell.
- the Sp110 polypeptide is predicted to contain an activation domain located in the region between the Sp100-like domain and the SAND domain, i.e., in the region between amino acids 109 and 454 of SEQ ID NO:2.
- a polypeptide containing this region or a derivative thereof is used to enhance or promote Sp110 activity.
- Sp110 contains a SAND domain, variations of which are found in Sp100, Sp140, AIRE-1 (Nagamine et al., Nature Genetics 17:393-397, 1997), nuclear phosphoprotein 72, and DEAF-1 (Gross et al., EMBO J. 15:1961-1970, 1996). It is predicted that the Sp110 SAND domain is a DNA-binding domain (Gibson et al., Trends Biochem Sci. 23:242-244, 1998).
- a polypeptide that contains a SAND domain (or derivative thereof), but lacks an activating domain is employed as an inhibitor of Sp110 activity in a cell, e.g., a cell cultured in vitro.
- an Sp110 polypeptide lacking the region extending from approximately amino acid 110 to amino acid 453 in SEQ ID NO:2. Such a polypeptide inhibits Sp110 activity because the SAND domain occupies some or all of the Sp110 binding sites, thereby blocking access of active Sp110 molecules to the binding sites.
- a membrane transport moiety e.g., the internalization peptide sequence derived from Antennapedia (Bonfanti et al., Cancer Res. 57:1442-1446) or an HIV tat peptide (U.S. Pat. No. 5,652,122) is conjugated to the SAND domain to facilitate entry of the SAND domain into living cells.
- the carrier moiety is a polypeptide fused to the SAND domain or polypeptide containing the SAND domain, e.g., at the amino terminus of the SAND domain-containing polypeptide.
- the full-length Sp110 polypeptide contains a plant homeobox domain (PHD). This is a cysteine-rich region that spans 50-80 amino acid residues and contains the motif Cys 4 -His-Cys 3 (Aasland et al., Trends Biochem. Sci. 20:56-59, 1995). This motif is found in many proteins that are involved in chromatin-mediated control of gene transcription. It is predicted that the Sp110 PHD functions in protein-protein or protein-DNA interactions.
- PHD plant homeobox domain
- the full-length Sp110 polypeptide contains a bromodomain. It is predicted that the Sp110 bromodomain functions catalytically in acetylation of histones.
- the bromodomain is an ⁇ helical motif found in many proteins involved in the regulation of gene transcription (Jeanmougin et al., Trends Biochem. Sci. 22:151-153, 1997). In general, the bromodomain is found in transcription factors that have catalytic domains. For example, SW12/SNF2 has a DNA-dependent ATPase domain (Laurent et al., Genes Dev.
- TAF II 250 (Dickstein et al., Cell 84:781-790, 1996) and TIF1 ⁇ (Fraser et al., J. Biol. Chem. 273:16199-16204, 1998) have kinase domains, and GCN5 has a histone acetyl-transferase (HAT) domain (Brownwell et al., Cell 84:843-851, 1996).
- HAT histone acetyl-transferase
- the bromodomain spans 110 amino acid residues and contains two additional a helices (Le Douarin et al., EMBO J. 15:6701-6715, 1996).
- the four predicted a helices were designated Z, A, B, and C.
- the Sp110 bromodomain of SEQ ID NO:2 includes the A, B, and C helices but lacks the Z helix. Some Sp1110 splice variants may have a Z helix.
- Sp110 polypeptides, and fragments and derivatives thereof can be obtained by any suitable method.
- Sp110 polypeptides can be produced using conventional recombinant DNA technology, as described in the Examples below.
- Guidance and information concerning methods and materials for production of polypeptides using recombinant DNA technology can be found in numerous treatises and reference manuals. See, e.g., Sambrook et al, 1989 , Molecular Cloning—A Laboratory Manual, 2 nd Ed., Cold Spring Harbor Press; Ausubel et al. (eds.), 1994 , Current Protocols in Molecular Biology , John Wiley & Sons, Inc.; Innis et al. (eds.), 1990 PCR Protocols, Academic Press.
- Sp110 polypeptides or fragments thereof can be obtained directly by chemical synthesis, e.g., using a commercial peptide synthesizer according to vendor's instructions. Methods and materials for chemical synthesis of polypeptides are well known in the art. See, e.g., Merrifield, 1963, “Solid Phase Synthesis,” J. Am. Chem. Soc. 83:21492154.
- Percent identity between amino acid sequences referred to herein is determined using the BLAST 2.0 program, which is available to the public at http://www.ncbi.nlm.nih.gov/BLAST. Sequence comparison is performed using an ungapped alignment and using the default parameters (Blossom 62 matrix, gap existence cost of 11, per residue gap cost of 1, and a lambda ratio of 0.85). The mathematical algorithm used in BLAST programs is described in Altschul et al., 1997 , Nucleic Acids Research 25:3389-3402.
- isolated DNA means DNA that has been separated from DNA that flanks the DNA in the genome of the organism in the which the DNA naturally occurs.
- the term therefore includes a recombinant DNA incorporated into a vector, e.g., a cloning vector or an expression vector.
- the term also includes a molecule such as a cDNA, a genomic fragment, a fragment produced by PCR, or a restriction fragment.
- the term also includes a recombinant nucleotide sequence that is part of a hybrid gene construct, i.e., a gene construct encoding a fusion protein.
- high stringency means the following: hybridization at 42° C. in the presence of 50% formamide; a first wash at 65° C. with 2 ⁇ SSC containing 1% SDS; followed by a second wash at 65° C. with 0.1 ⁇ SSC.
- substantially pure polypeptide means a polypeptide separated from components that naturally accompany it.
- a polypeptide is substantially pure when it is at least 80%, by weight, free from the proteins and other organic molecules with which it is naturally associated. Purity can be measured by any suitable method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- a chemically synthesized polypeptide or a recombinant polypeptide produced in a cell type other than the cell type in which it naturally occurs is, by definition, substantially free from components that naturally accompany it.
- “conservative amino acid substitution” means a substitution within an amino acid family. Families of amino acid residues are recognized in the art and are based on physical and chemical properties of the amino acid side chains. Families include the following: amino acids with basic side chains (e.g. lysine, arginine, and histidine); amino acids with acidic side chains (e.g., aspartic acid and glutamic acid); amino acids with uncharged polar side chains (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine); amino acids with nonpolar side chains (e.g.
- amino acid can belong to more than one family.
- a full-length Sp110 polypeptide, Sp110 polypeptide fragments containing individual Sp110 domains, or other antigenic Sp110 fragments can be used to produce Sp110-specific antibodies.
- An example of an Sp110 fragment that can be used to elicit Sp110-specific antibodies is a polypeptide consisting of amino acids 219-235 of SEQ ID NO:2.
- the Sp110 specific antibodies can be readily obtained, without undue experimentation, through application of conventional techniques.
- Sp110 appears to play a role in inhibiting viral replication and facilitating differentiation of cells, e.g., myeloid cells, and activation of cells involved in host defense.
- an Sp110 polypeptide can be used therapeutically to treat myeloid malignancies by virtue of its ability to promote myeloid cell differentiation.
- the nuclear body, of which Sp110 is a structural component is disrupted in various human disorders, including acute promyelocytic leukemia and viral infections.
- an Sp110 polypeptide (or derivative thereof) is introduced into a cell in vitro or in a mammal to enhance cellular defense mechanisms.
- Sp110 is administered therapeutically to treat inflammation or to achieve alteration in lipid profiles.
- a preformed Sp110 polypeptide can be introduced into a cell using conventional techniques for transporting proteins into intact cells, e.g., by fusing the polypeptide to the internalization peptide sequence derived from Antenntapedia (Bonfanti et al., Cancer Res. 57:1442-1446) or to an HIV tat peptide (U.S. Pat. No. 5,652,122).
- the Sp110 polypeptide can be expressed in the cell following introduction of an Sp110-encoding DNA, e.g., in a conventional expression vector, according to the invention.
- Sp140 is concurrently introduced into the cell, or co-expressed in the cell, so that the Sp140 can recruit the Sp110 into nuclear bodies.
- the biological activities of Sp110 include co-activation of nuclear hormone receptors, e.g., retinoic acid receptors (RARs), RXRs, LXR, FXR, peroxisome proliferator-activated receptors (PPARs), including PPAR ⁇ and PPAR ⁇ , glucocorticoid receptors, estrogen receptors, progesterone receptors, androgen receptors, and orphan nuclear hormone receptors.
- Nuclear hormone receptors mediate signal transduction in various cellular responses.
- Sp110 appears to enhance expression of nuclear hormone-responsive genes by binding to a nucleotide sequence adjacent to the nuclear hormone response element and directly or indirectly enhancing gene expression. Activities of RARs and RXRs are important in cellular differentiation. Activities of PPAR ⁇ and PPAR ⁇ are important in fatty acid metabolism and inflammation. Activities of FXR and LXR are important for cholesterol metabolism.
- an Sp110 polypeptide can be supplied in a therapeutic method.
- Sp110 may augment PPAR ⁇ 's effect on lipid metabolism, potentially attenuating cardiac hypertrophy.
- Sp110 may alter PPAR ⁇ regulation of lipid storage, potentially treating obesity.
- an Sp110 derivative can be used to inhibit FXR receptors, thereby enhancing conversion of cholesterol to bile acids.
- Sp110 is used to block estrogen receptors in treatment of estrogen responsive tumors.
- the invention includes inhibitors of Sp110 activity, screening methods for identifying inhibitors of Sp110 activity, and methods of inhibiting Sp110 activity in, cells in vitro or in a mammal
- polypeptide predicted to dimerize with endogenous Sp110 polypeptides to form an inactive dimer is a polypeptide that includes amino acids 1-453 of the Sp110 sequence fused to amino acids 533-689 of the Sp110 sequence (amino acids 1-453 of SEQ ID NO:2 fused to amino acids 533-689 of SEQ ID NO:2).
- Such a polypeptide includes the entire Sp110 amino acid sequence except the Sp110 SAND domain, which is predicted to be required for recognizing and binding to Sp110 binding sites in DNA, but not required for Sp110 dimerization.
- An example of a polypeptide predicted to recognize and occupy Sp110 binding sites (nucleotide sequences) in DNA without causing transcriptional activation is an Sp110 SAND domain or fragment thereof.
- Polypeptides and other molecules, e.g., small molecules, that inhibit or promote Sp110 activity can be identified by screening methods provided by the invention.
- the type of screening method employed will depend on the type of inhibition mechanism chosen.
- One general approach is based on Sp110 dimerization, which is predicted to be necessary for Sp110 biological activity.
- One variation on this approach is to provide a molecule that interferes with Sp110 dimerization.
- Another variation on this approach is to provide a polypeptide that dimerizes with endogenous Sp110 polypeptides to form an inactive dimer.
- a second general approach is to provide a molecule that binds to (blocks) a site on the Sp110 polypeptide that interacts with nuclear hormone receptors.
- a third general approach is to interfere with binding of active Sp110 dimers to Sp110-binding DNA sequences in the genome.
- One variation on this approach is to provide a molecule, e.g., a polypeptide, that binds to (blocks) Sp110-binding DNA sequences.
- Another variation on this approach is to provide an oigonucleotide based on an Sp110-binding DNA sequence in the genome. The oligonucleotide binds to (blocks) the DNA-binding site(s) on the Sp110 dimer.
- PBC Primary biliary cirrhosis
- the invention provides methods for identifying and characterizing novel autoantibody markers of disease state and prognosis in PBC patients. Serum samples from PBC patients are tested for the presence of antibodies that react with Sp110. Various types of methods for detecting and quantifying such antibody-antigen reactions are known and can be employed.
- PBC-related autoantibodies are detected and characterized in methods such as conventional immunoblotting (Western) techniques, wherein an Sp110 polypeptide (or Sp110 polypeptide fragment) is employed as an antigen.
- an Sp110 polypeptide or Sp110 polypeptide fragment
- the Sp110 polypeptide is subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted (transferred) onto a suitable membrane, e.g., nitrocellulose, where the Sp110 antigen is immobilized.
- SDS-PAGE SDS-polyacrylamide gel electrophoresis
- Sera from PBC patients are diluted as necessary and contacted with the Sp110 antigen-bearing membrane under suitable conditions for specific binding of the immobilized antigen to an anti-Sp110 antigen, if one is present. After suitable washing steps, bound antibody is detected.
- Detection of bound antibody can be accomplished by any suitable method.
- labeled protein A which binds to IgG with high specificity and high affinity
- the protein A can be labeled in any of various ways.
- Useful types of label include a conjugated calorimetric enzyme, e.g., horseradish peroxidase, a conjugated fluorochrome, e.g., FITC, or a radioactive atom, e.g., 125 I.
- Immunoblot assay results can be quantitated, for example, by incorporating internal standards and a suitable optical scanning device.
- suitable positive and negative controls are employed in testing patient sera.
- other nuclear body components such as Sp100, Sp140 polypeptides can be tested simultaneously, e.g., on the same immunoblot membrane.
- PBC-related autoantibodies are detected and quantitated using techniques designed for rapid, high-volume screening, e.g., microtiter plate ELISA techniques. Such techniques are known in the art and can be employed in practicing the present invention without undue experimentation.
- a nucleotide sequence in the EST database that encodes a polypeptide homologous to the N-terminal portions of Sp100 and Sp140 was obtained from the IMAGE consortium (accession number AA431918). This material proved unsuitable to prepare probes for screening a cDNA library because it was highly contaminated with unrelated cDNAs.
- oligonucleotides were synthesized based upon the sequence of the EST clone (5′-TTGAATTCATGGAAGAGGCTCTTTTTCAG-3′ (SEQ ID NO:10) and 5′-TTGAATTCCTTCTGCTAGGCCAGTTGG-3′ (SEQ ID NO:11)) and the polymerase chain reaction (PCR) was used to synthesize a fragment of the cDNA.
- the PCR product was radiolabeled and used to screen a ⁇ GT10 cDNA library prepared from human spleen (Clontech, Palo Alto, Calif.).
- Six cDNA clones from among approximately one million bacteriophages hybridized with the radiolabeled probe and were isolated by plaque purification.
- the cDNA encoding Sp110 was 2,337 base pairs long, with an open reading frame from nucleotides 78 to 2144 encoding a protein containing 689 amino acids (FIGS. 1 and 3). The start codon was preceded by an in-frame stop codon, indicating that this is a full-length cDNA.
- the amino acid residues at 241 to 605 of Sp110 were essentially identical to residues 1 to 365 of a previously reported polypeptide designated nuclear phosphoprotein 72 (Kadereit et al., J. Biol. Chem. 268: 24432-24441, 1993). In this region, the amino acid sequence of Sp110 differed from that of nuclear phosphoprotein 72 at amino acid 580 (I-M).
- the N-terminal portion of Sp110, between amino acid residues 6 and 159 was 49% identical to the N-terminal portions of both Sp100 (Szostecki et al., J. Immunol. 145:4338-4347, 1990) and Sp140 (Bloch et al., J. Biol. Chem. 46:29198-29204, 1996).
- a second region of homology between Sp110 and both Sp100b and Sp140 was present between amino acid residues 452 and 532. In this region, Sp110 was 53% identical to Sp100b (Dent et al., Blood 88:1423-1436, 1996) and 49% identical to Sp140.
- Sp110 amino acid residues 537 to 577 spanned a plant homeobox domain (Aasland et al., Trends Biochem. Sci. 20:56-59, 1995), and amino acid residues 606 to 674 contained the A, B, and C helices of a bromodomain (Jeanmougin et al., Trends Biochem Sci. 22:151-153, 1997).
- the plant homeobox domain and bromodomain of Sp110 were 71% and 54% identical to the corresponding regions in Sp140. In addition, these portions of Sp110 were 56% and 46% identical to the corresponding regions in murine TIF1 ⁇ .
- the level of Sp110 mRNA in human tissues was determined by hybridizing membranes containing 2.5 ⁇ g of poly(A) + -selected RNA from human tissues (multiple tissue Northern blots, Clontech Laboratories, Palo Alto, Calif.) with a 32 P-radiolabeled 1.4 kb XbaI restriction fragment of the Sp110 cDNA.
- the human tissues represented on the membranes were spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. The membranes were washed under stringent conditions and exposed to autoradiographic film for one hour.
- the membranes were hybridized with a 32 P-radiolabeled ⁇ -actin cDNA probe. The membranes were washed under stringent conditions and exposed to autoradiography film for 30 minutes.
- RNA was prepared from the myeloid precursor cell lines HL60 and NB4 (HL60 cells are available from the American Type Culture Collection, Manassas, Va.). RNA was extracted from these cell lines using the guanidinium isothiocyanate-cesium chloride method (Sambrook et al., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989). The HL60 cells were maintained in RPMI supplemented with 10% fetal calf serum, L-glutamine (2 mM), penicillin (200 units/ml), and streptomycin (200 mg/ml).
- NB4 cells were treated for 48 hours with all trans retinoic acid (ATRA) (1 ⁇ M). Following this treatment, the level of Sp110 mRNA was increased in NB4 cells, which indicates that differentiation of NB4 cells is associated with increased expression of Sp110.
- ATRA trans retinoic acid
- HL60 cells were treated with IFN- ⁇ (200 units/ml) for 48 hours. A marked increase in Sp110 mRNA was observed.
- Sp110 expression was also examined in human coronary artery smooth muscle cells (hCASMCs) and human umbilical vein endothelial, cells (HUVECs) following exposure to IFN ⁇ (200 u/ml). Expression of Sp110 mRNA was induced within 4 hours and reached a maximum level between 8 and 24 hours. Similar results were obtained after treating hCASMCs or HUVECs with IFN ⁇ or IL-1 ⁇ and TNF ⁇ . Sp110 gene expression was also markedly induced in hearts of mice treated with endotoxin, suggesting that inflammatory mediators increase Sp110 mRNA levels in cardiac myocytes.
- an E1-deleted, recombinant adenovirus vector containing Sp110 the cDNA encoding Sp110 was cloned into the NotI and BamHI sites of pAd.RSV 4 , which contained the Rous sarcoma virus long-terminal repeat promoter and the SV40 polyadenylation signal.
- the plasmid containing Sp110 was co-transfected into 2093 cells with pSM17. Homologous recombination between the two plasmids resulted in an adenovirus (Ad.Sp110) that contained Sp110 sequences in place of E1 sequences.
- Recombinant viruses in a plaque were amplified in 293 cells, and a high-titer stock was prepared.
- the 293 cells were grown in low glucose (1 g/L)-DMEM supplemented with 10% horse serum.
- the absence of replication-competent adenovirus in the viral stock was confirmed by the failure of Ad.Sp110 to produce cytopathic changes in A549 lung carcinoma cells.
- PCR failed to amplify a DNA fragment corresponding to the E1 region of adenovirus using oligonucleotides and the Ad.Sp110 stock.
- An adenovirus vector containing the cDNA encoding Sp140 was described previously in (Bloch, et al., Mol. Cell. Biol. 19:4423-4430,1999).
- the fusion protein was purified from E. coli proteins as described in (Smith et al., Gene 67:31-40, 1988). Primary immunizations of three rats was performed using 50 ⁇ g of purified protein emulsified in complete Freund's adjuvant for each animal. Two subsequent booster injections consisting of 50 ⁇ g of protein were given at two-week intervals.
- rat anti-Sp110 antiserum reacted with Sp110 in extracts prepared from Ad.Sp110-infected HEp-2 cells, but not with Sp140 in extracts prepared from Ad.Sp140-infected HEp-2 cells or with Sp100, which is normally expressed in HEp-2 cells.
- rat anti-Sp140 antiserum previously prepared against amino acid residues 131-391 of Sp140 (Bloch et al., J. Biol. Chem. 46:29198-29204, 1996), reacted with Sp140, but not with Sp110 or Sp100.
- rat anti-Sp110 antibodies were used to stain NB4 cells before and after treatment with RA.
- NB4 cells were treated with ATRA and stained with rat anti-Sp110 antiserum and human serum containing antibodies directed against Sp100. Sp110 co-localized with Sp100 in nuclear bodies.
- Sp110 adenovirus-mediated gene transfer was used to express Sp1110 in human cell lines in which it is not normally expressed.
- MOI multiplicity of infection
- Sp110 did not localize to nuclear bodies in these cells, but instead appeared to produce a granular nuclear staining pattern with prominent staining near the nuclear membrane. Cytoplasmic staining was also observed in a few cells.
- the contrasting results obtained using the leukocyte cell line NB4 and Ad.Sp110-infected HEp-2 cells can be reconciled with the present result if Sp140, another leukocyte-specific nuclear body component, recruits Sp110 to the nuclear body.
- HEp-2 cells were infected with both Ad.Sp140, at an MOI of 50, and Ad.Sp110, at an MOI of 25. At an MOI of 50, essentially all of the HEp-2 cells expressed detectable Sp140 within nuclear bodies. In cells infected with Ad.Sp140 alone, anti-Sp110 antiserum did not stain nuclear bodies, confirming that anti-Sp110 antiserum did not cross-react with Sp140. In cells infected with both Sp110 and Sp140, Sp110 localized to nuclear bodies and co-localized with Sp100-containing nuclear bodies. These results demonstrated that Sp140 enhances localization of Sp110 to the nuclear body.
- Sp110 also acted as a co-activator of PPAR ⁇ .
- COS cells were co-transfected with PPAR ⁇ and a reporter gene containing three copies of the PPAR response element (PPRE)
- PPRE PPAR response element
- Sp110 markedly enhanced agonist-induced expression of the reporter gene compared with the effect of PPAR ⁇ expressed alone.
- Sp110 may interact with nuclear hormone receptors via an LXXLL domain.
- oligonucleotides and PCR were used to prepare a mutant Sp110 protein (Sp110m) in which two of the three leucine residues were changed, one to valine and one to alanine (LXXVA).
- Sp110 enhanced signal transduction through the retinoic acid receptor ⁇ (RAR ⁇ ) (LaMorte et al., Proc Natl Acad Sci USA 95:4991-4996, 1998) and, in contrast to the results obtained with PPAR ⁇ , expression of Sp110m with RAR ⁇ also enhanced expression of the reporter gene. Similarly, both Sp110 and the Sp110 mutant enhanced signal transduction through the PPAR ⁇ receptor.
- RAR ⁇ retinoic acid receptor ⁇
- both Sp110 and the Sp110 mutant enhanced signal transduction through the PPAR ⁇ receptor.
- PPAR ⁇ interacted with the N-terminal portion of CBP/p300 between amino acid residues 39 and 221.
- the mammalian two-hybrid system was used as an assay.
- GAL4 DNA-binding domain (GAL4) fused to CBP (GAL4-CBP) and a luciferase reporter gene containing GAL4 response elements were expressed in COS cells with either Sp110 fused to the herpes simplex virus VP16 activation domain (VP16-Sp110) or VP16 alone.
- GAL4-CBP GAL4 DNA-binding domain fused to CBP
- VP16-Sp110 a luciferase reporter gene containing GAL4 response elements
- Sp110 interacts, either directly or indirectly, with CBP.
- the site of functional interaction between Sp110 and CBP was mapped more specifically to amino acid residues 271-720 of CBP.
- the Sp110-CBP functional interaction domain is therefore distinct from the PPAR ⁇ -CBP interaction domain.
- the N-terminal or C-terminal portions of Sp110 were fused to VP16 and expressed in COS cells together with GAL4CBP and a reporter gene.
- the C-terminal portion which contained the PHD and the bromodomain, enhanced GAL4-CBP-induced expression of the reporter gene, but the N-terminal portion, which contained the Sp100-like region, did not.
- studies can be carried out to further delineate the domains that mediate functional interaction between Sp110 and CBP and to test whether Sp110 interacts with CBP directly.
- Sp110 does not contain motifs, such as acetyltransferase (as in CBP/p300) or kinase domains (as in TIF1 ⁇ ), that are known to activate gene transcription.
- motifs such as acetyltransferase (as in CBP/p300) or kinase domains (as in TIF1 ⁇ ), that are known to activate gene transcription.
- DNA segments encoding fragments of Sp110 fused to GAL4 were expressed with a reporter gene in COS cells.
- Neither the N-terminal (Sp100-like domain), nor the C-terminal (PHD/bromodomain) portions of Sp110 increased expression of the reporter gene.
- fusion proteins containing the middle portion of the protein putative activation domain and SAND domain
- the mechanism by which Sp110 enhances PPAR ⁇ -mediated gene transcription can be investigated, as described below, by identifying proteins that interact with the activation domain and SAND domain.
- This experiment tests the possibility that Sp110 enhances expression of a reporter gene under the control of the native promoter region of CPTI, a gene that is regulated by PPAR ⁇ .
- Co-transfection studies are performed in COS cells using a luciferase reporter construct that contains a CPTI gene promoter having the PPRE (AGGGAAaAGGTCA; SEQ ID NO:_______).
- the effect of co-expression of Sp110 and PPAR ⁇ on luciferase activity is compared to that of Sp110, PPARR ⁇ , or control vectors alone.
- An expected result is that Sp110 enhances PPAR ⁇ -mediated expression of the reporter gene under the control of the CPTI promoter region.
- Sp110 may enhance luciferase expression by interacting with other regulatory elements within the CPTI promoter region.
- the effect of Sp110 on luciferase activity requires PPAR ⁇
- the effect of Sp110 on a luciferase reporter plasmid that has a mutated PPRE is determined. If Sp110 enhances CPTI promoter-driven luciferase activity by interacting with PPAR ⁇ , then an expected result is that Sp110 has no effect on expression of the reporter plasmid with the mutated PPRE.
- the fibroblast cell line 3T3-L1 can be induced to differentiate into cells that resemble white adipocytes. These cells normally express low levels of enzymes involved in mitochondrial fatty acid oxidation.
- Sp110 enhances PPAR ⁇ -mediated upregulation of mitochondrial fatty acid oxidation gene expression
- Sp110 is overexptessed in 3T3-L1 cells using an adenovirus vector (Ad.Sp110).
- An unrelated protein, green fluorescent protein (GFP) is expressed as a control using a second adenovirus vector (Ad.GFP).
- Ad.Sp110 Ad.Sp110
- Ad.GFP second adenovirus vector
- RNA blot hybridization will be performed to measure the effect of Sp110 (compared with GFP) on expression of three fatty acid oxidation genes (MCAD, LCAD, and CPT-I) in the presence or absence of the PPAR(X agonist WY 14,643.
- 3T3 L1 cells are infected with either Ad.Sp110 or Ad.GFP, and the rate of palmitate oxidation is determined (Gulick et al., Proc. Natl. Acad. Sci., USA, 91:11012-11016, 1994). Seventy-two hours after infection, the cells are incubated with [ 14 C] palmitate.
- the tissue culture plates contain a central well with, a piece of filter paper. After 6 hours, the 14 Co 2 is released from tissue culture medium by addition of 6 N HCl and 14 CO 2 is collected overnight by alkalinization of the filter paper with 2 N NaOH. 14 CO 2 is measured by scintillation counting of the filters.
- Sp110 but not GFP, enhances Wy 14,643-induced (PPAR ⁇ agonist-induced) expression of genes involved in fatty acid oxidation and increase palmitate oxidation in 3T3-L1 cells. Because the effect of Sp110 on PPAR ⁇ is expected to require direct interaction between the two proteins, Sp110 is expected to be more effective than Sp110m at producing these changes. If Sp110 and Sp110m are equally effective at inducing fatty acid oxidation, the putative LXXLL interaction domain in Sp110 is deemed non-crucial for this effect. In that event, studies to define alternative interaction sites between PPAR ⁇ and Sp110 could be carried out.
- 3T3-L1 cells express relatively low levels of PPAR ⁇ . In fact, these levels may be too low to detect any effect of Sp110 on genes normally regulated by PPAR ⁇ . Thus, if there appears to be no enhancement of expression of genes involved in fatty acid oxidation following infection with Ad.Sp110, the studies are performed using an adenovirus vector encoding PPAR ⁇ . Successful production of PPAR ⁇ is confirmed using immunoblots and a commercially available anti-PPAR ⁇ antibody. 3T3-L1 cells will be infected with Ad.GFP, Ad.Sp110, Ad.PPAR ⁇ , or both Ad.Sp110 and Ad.PPAR ⁇ . The effect of Ad.PPAR ⁇ and Ad.Sp110 (together) on the expression of fatty acid oxidation genes and palmitate oxidation rates is compared to the effect of Ad.Sp110, Ad.PPAR ⁇ , and Ad.GFP alone.
- Inflammatory cytokines such as IL-1 induce expression of IL-6 and COX-2 in smooth muscle cells (SMCs). This expression can be blocked, however, if the SMCs are; treated with PPAR ⁇ agonists (Staels et al., J. Clin. Invest. 103:1489-1498, 1999). Endogenous Sp110 expression in SMCs was enhanced by treatment with inflammatory cytokines. Thus, Sp110 is expected to enhance PPAR ⁇ -mediated inhibition of the inflammatory response in SMCs.
- Sp110 also is expected to augment the ability of PPAR ⁇ to inhibit COX-2 gene expression
- SMCs are infected with Ad.Sp110 and subsequently treated with IL-I as described above.
- the cells are treated with increasing amounts of the PPAR ⁇ agonist Wy14,643 and the concentration of COX-1 and COX-2 protein will be measured using immunoblot techniques.
- Parallel experiments are conducted with Ad.GFP as a control.
- Sp110 The biological function of Sp110 can be assessed in numerous ways, including studies in which it is overexpressed (as can be done to investigate its role in PPAR ⁇ -mediated signal transduction) and studies in which oligopeptides are used as inhibitors (as can be done to inhibit the ligand-dependent interaction between PPAR ⁇ and Sp110).
- Two complementary oligonucleotides encoding a peptide that spans seven amino acids on either side of the LXXLL domain of Sp110 are synthesized and ligated, in frame, to GAL4 in a eukaryotic expression plasmid (pGAL-LXXL).
- this expression plasmid are co-transfected into COS cells with plasmids encoding PPAR ⁇ , Sp110, and a reporter gene construct in which the reporter is driven by PPRE.
- cells are transfected in parallel with a plasmid encoding pGAL alone.
- GAL4 as a fusion partner facilitates nuclear localization of the oligopeptide.
- successful production of the GAL4-oligopeptide fusion protein in transfection assays is confirmed by immunoblotting with anti-GAL4 antibodies.
- Expression of the GAL4-oligopeptide in COS cells is expected to block agonist-specific, Sp110-mediated, activation of PPAR ⁇ .
- hCASMCs To examine the effect of inhibiting the interaction between PPAR ⁇ and Sp110 in hCASMCs, an adenovirus vector encoding GAL4-LXXLL and a control virus encoding GAL4 fused to the same amino acid residues in random rearrangement are prepared. hCASMCs are treated with IL-1 and subsequently infected with either Ad.GAL4-LXXLL or the control adenovirus vector. The production of IL-6 and the induction of COX-2 are assayed as described above.
- DNA molecules encoding portions of Sp110 are ligated into the eukaryotic expression vector pVP16 in-frame with the HSV VP16 activation domain.
- Each of the resulting plasmids are co-transfected into COS cells with a second plasmid encoding PPAR ⁇ and a reporter gene containing a PPRE.
- Successful, production of each fragment of Sp110 is confirmed using immunoblots and an antibody directed against VP16.
- each VP16-Sp110 fusion protein to enhance reporter gene expression in the presence of PPAR ⁇ and agonist provides evidence for a functional interaction between a given Sp110 portion and PPAR ⁇ .
- Control experiments are conducted to rule out the possibility that VP16-Sp110 fusion proteins activate the reporter gene in the absence of PPAR ⁇ .
- the inability of PPAR ⁇ and VP16-Sp110 fusion proteins to activate reporter gene expression from a plasmid that lacks the PPRE will be confirmed.
- DNA molecules encoding portions of PPAR ⁇ will be ligated into a eukaryotic expression plasmid in-frame with GAL4.
- the plasmids will be co-transfected with a plasmid encoding Sp110 fused to VP16 and a reporter gene with an upstream GAL4 response element.
- Gene expression mediated by GAL4-PPAR ⁇ -fragment and Sp110 will be compared to that mediated by the same GAL4-PPAR ⁇ -fragment and control plasmid.
- the ability of VP16-Sp110 to enhance GAL4-PPAR ⁇ -fragment-induced reporter gene expression will be evidence of an interaction between Sp110 and a PPAR ⁇ fragment.
- the interaction domains should include the LXXLL domain of Sp110 and the ligand-binding “activation function 2” (AF2) portion of PPAR ⁇ .
- Sp110 is predicted to interact directly with PPAR ⁇ .
- a GST-Sp110 fusion protein is prepared and tested in vitro for interaction with 35 S-radiolabeled PPARA.
- DNA encoding Sp110 is ligated in-frame with DNA encoding glutathione-S-transferase (GST) in the prokaryotic expression plasmid pGEX so as to encode a GST-Sp110 fusion protein.
- GST-Sp110 fusion protein is expressed in E. coli, affinity-purified, and immobilized on Sepharose beads.
- DNA encoding PPAR ⁇ are used to prepare 35 S-radiolabeled protein by in vitro transcription and translation and will be incubated with Sepharose-GST-Sp110 (or Sepharose-GST alone) in the presence and absence of PPAR ⁇ agonist. Bound and radiolabeled PPAR ⁇ is eluted from Sepharose-GST-Sp110 (or Sepharose-GST) by boiling in SDS/PAGE sample buffer, and the eluant will be fractionated by SDS/PAGE.
- a mammalian two-hybrid assay was used to demonstrate a functional interaction between the PHD/bromodomain of Sp110 and amino acids 271-720 of CBP.
- Sp110 may also interact directly with CBP.
- a GST-CBP(271-720) fusion protein will be prepared (as described above for Sp110) and exposed to 35 S-radiolabeled Sp110.
- An 35 S-radiolabeled nuclear body component, PML can serve as a positive control for interaction with CBP, as PML interacts with CBP in this portion of the protein (Doucas et al., Proc. Natl. Acad. Sci. USA, 96:2627-2632, 1999).
- a Sepharose-GST-CBP (271-720) fusion protein but not Sepharose-GST alone, would be expected to retain radiolabeled Sp110.
- CBP has been described as a “platform” protein because it interacts with many other proteins.
- proteins that interact with CBP at amino acid residues 271-720 are: RXR, STAT2, CREB, JUN, MYYB, ELK1, SREBP, and SAP1A (Giles et al., Trends Genetics, 14:178-183, 1998).
- at least one other protein may mediate the functional interaction between these two proteins. If a direct interaction between Sp10 and CBP cannot be demonstrated using GST pulldown experiments, then the mammalian two-hybrid system will be used to further delineate the site in CBP that mediates functional interaction with Sp110.
- a candidate gene approach will involve obtaining cDNAs encoding proteins that are known to interact with the identified portion of CBP. Proteins encoded by these cDNAs will be tested for interaction with Sp110 using a combination of GST pull-down and mammalian two-hybrid assays. If none of the candidate genes interacts with Sp110, then the yeast two-hybrid system will be used to identify cDNAs encoding proteins that link CBP and Sp110. A DNA fragment encoding the PHD/bromodomain of Sp110, and a DNA fragment encoding the portion of CBP that mediates functional interaction with Sp110, will each be used to screen a human leukocyte cDNA library. Complementary DNAs encoding interacting proteins will be divided into groups that interact with Sp110, CBP, or both. Verification of “true” protein-protein interactions are then performed, as described below.
- Sp110 appears to enhance expression of nuclear hormone responsive genes by binding to a nucleotide sequence adjacent to the nuclear hormone response element and directly or indirectly enhancing gene expression.
- the sand domain of Sp110 may mediate DNA binding. By interacting directly with DNA, Sp110 may enhance gene expression independent of the LXXLL motif.
- a GAL4-Sp110 fusion protein is capable of activating expression of a reporter gene driven by the GAL4 response element, and neither the N-terminal, which contains the Sp100-like domain, nor the C-terminal, which contains the LXXLL/PHD/bromodomain) of Sp110 are required to mediate enhanced expression of the reporter gene.
- the middle portion of Sp110 contains a SAND domain, an amino acid sequence motif that has been observed in several proteins that regulate gene transcription.
- a DNA fragment encoding that domain will be used as “bait” in the yeast two-hybrid assay.
- the DNA fragment are ligated into plasmid pGBKT7 (Clontech) and transferred into yeast with a leukocyte cDNA library prepared in pGADT7.
- the transformed yeast will be screened for the ability to grow on His ⁇ medium and colonies that grow on this medium will be tested for ⁇ -galactosidase ( ⁇ -gal) activity.
- Complementary DNAs are recovered from positive yeast clones and re-tested for interaction with bait by a second round of transformation in yeast.
- Clones encoding proteins that specifically interact with the Sp110 activation domain, but not the unrelated protein, will be sequenced and further characterized
- proteins that interact with the activation domain are identified by purifying interacting proteins from cell extracts using recombinant Sp110 protein linked to Sepharose beads. Purified proteins will be fractionated in polyacrylamide gels, transferred to IMMOBILONTM filters, and subjected to amino acid microsequencing. These techniques have been used previously to purify and identify the predominant autoantigen in patients with autoimmune sensorineural hearing loss (Bloch et al., Archives of Otolaryngology-Head and Neck Surgery 121:1167-1171, 1995).
- Adenovirus vectors containing cDNAs encoding Sp140, Sp110, and Sp100 produce high levels of protein in human 293 cells. Aliquots of cell lysates sufficient to screen 5,000 sera for each of these antigens are prepared. Cell lysates are boiled in loading buffer, fractionated in an 8% polyacrylamide gel, and transferred to nitrocellulose membranes. A miniblot apparatus is applied to the membrane. This permits screening of 20 sera on each membrane. As a preliminary screen, patient serum is diluted 1:200 in PBS containing 5% nonfat dry milk and incubated for one hour at room temperature with the nitrocellulose.
- Membranes are washed three times with PBS and incubated with horseradish peroxidase (HRP) conjugated-protein A diluted 1:5000 in PBS. Filters are washed three times in PBS, incubated with chemiluminescence reagent, and then exposed to film. If a serum sample appears to contain antibodies directed against the recombinant protein, then a second immunoblot is performed. This second membrane has two lanes, one containing protein from 293 cells infected with adenovirus encoding the nuclear body protein, and the second containing protein from cells infected with the control adenovirus.
- HRP horseradish peroxidase
- the diagnosis of PBC in the 370-patient cohort is established based on the presence of abnormal liver function tests, AMA (titer ⁇ 1:20) and liver biopsy compatible with PBC.
- the findings on liver biopsy are classified into four stages (portal hepatitis, periportal hepatitis, septal fibrosis and/or bridging necrosis, cirrhosis).
- the cohort includes 234 women and 36 men.
- the date of presentation was defined as the first documentation of abnormal liver enzymes.
- the median age at presentation is 52 years (range 24-81).
- the median length of follow-up is nine years (range 1-27).
- Symptoms of PBC in these patients include pruritis, jaundice, portosystemic encephalopathy, bleeding varices, edema and ascites. Endpoints of the study are liver transplantation, death from liver disease and death from other causes.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- [0001] Work on the invention was supported in part by National Institutes of Health grants AR-01866 and DK-051179. Therefore, the government has certain rights in the invention.
- This invention relates to molecular biology, biochemistry, cell biology, medicine and medical diagnostics.
- The nuclear body is a multiprotein complex located within the nuclei of cells. The nuclear body is also known as
nuclear domain 10, PML oncogenic domain, and the Kr body. Immunohistochemical staining typically indicates 5-30 nuclear bodies within a nucleus. The nuclear bodies appear as discrete, punctate regions. The number of nuclear bodies in the cell, and the intensity of antibody staining of these structures, increase in response to heat shock and viral infection, as well as following exposure to interferons and heavy metals (Ascoli et al., J. Cell Biol. 112:785-795, 1991). The nuclear body appears to be involved in the regulation of gene transcription. Nascent RNA polymerase II transcripts have been found within the nuclear body (LaMorte et al., Proc. Natl. Acad. Sci. USA 95:4991-4996, 1998), and the nuclear body is a preferred site for transcription of viral genes (Ishov et al., J. Cell. Biol.138:5-16, 1997). - Promyelocytic leukemia (PML) protein is a component of the nuclear body. PML protein is involved in several cellular processes. For example, PML protein regulates cell growth (Wang, et al.,Science 279:1547-1551, 1998) and may mediate apoptosis (Wang, et al., Nature Genetics 20:266-272, 1998; Quignon et al., Nature Genetics 10:259-265, 1998). PML protein also recruits cAMP response element-binding protein (the CREB-binding protein or CBP) to the nuclear body and functions as a potent nuclear hormone receptor co-activator (Doucas et al., Proc. Natl. Acad. Sci. USA 96:2627-2632, 1999).
- In addition to its involvement in gene transcription, the nuclear body is a target of autoantibodies in the sera of patients who have primary biliary cirrhosis (P BC), an autoimmune disease (Hodges et al.,Am. J. Hum. Genet. 63:297-304, 199&; Melnick et al., Blood 93: 3167-3215, 1999; Stemsdorf et al., Immunobiology 198:307-331, 1997). PBC patients carry autoantibodies directed against Sp100 (Speckled 100 kDa), a polypeptide component of the nuclear body (Szostecki et al., J. Immunol. 145:4338-4347, 1990). Two splice variants of Sp100, designated Sp100b and Sp100-HMG, have also been found (Dent et al., Blood 88:1423-1436, 1996; Seeler et al. Proc. Natl. Acad. Sci. USA. 95:7316-7321, 1998; Lehining et al., Proc. Natl. Acad. Sci. USA 95:7322-7326, 1998). These proteins interact with members of the heterochromatin protein 1 (HP1) family of non-histone chromosomal proteins. When bound to a promoter, the Sp100 proteins and HP1 behave as transcriptional repressors in transfected cells. These observations suggest that the nuclear body in general, and the Sp100 proteins in particular, may maintain chromatin architecture and regulate gene transcription (Seeler, et al. Proc. Natl. Acad. Sci. USA 95:7316-7321, 1998 and Lehming et al., Proc. Natl. Acad. Sci. USA 95:7322-7326).
- Sera from PBC patients have also been used to identify a leukocyte-specific component of the nuclear body designated Sp140 (Bloch et al.,J. Biol. Chem. 46:29198-29204, 1996). The N-terminal portion of Sp140 exhibits sequence homology with the N-terminal segments of the Sp100 proteins. The middle region of Sp140 contains a “SAND” domain (Gibson et al., Trends Biochem. Sci. 23:242-244, 1998), and the C-terminal portion of Sp140 contains a plant homeobox domain and a bromodomain.
- A full length cDNA encoding Sp110 heckled 110), a novel 110 kDa polypeptide, has been discovered and characterized. It has been discovered that Sp110 is a component of the nuclear body, is expressed in leukocytes, and is also expressed in other types of cells, including endothelial cells, smooth muscle cells, liver cells and heart cells, after contact with, cytokines, including tumor necrosis factor,
interleukin 1, and interferons. Other discoveries include the following: Sp140 recruits Sp110 to the nuclear body, Sp110 functions as an activator of gene transcription, and Sp110 serves as a nuclear hormone receptor co-activator. - Based on these and other discoveries, the invention features an isolated DNA containing a nucleotide sequence whose complement hybridizes under stringent hybridization conditions to a DNA molecule whose nucleotide sequence consists of nucleotides 405 to 797 of the Sp110 cDNA (SEQ ID NO:1). In some embodiments, the isolated DNA also includes at least one of the following: a nucleotide sequence encoding a domain having at least 80% sequence identity with amino acids 6-109 (Sp100-like domain) of the Sp110 polypeptide (SEQ ID NO:2); a domain having at least 80% sequence identity with amino acids 454-532 of SEQ ID NO:2 (SAND domain); a domain having at least 80% sequence identity with amino acids 537-577 of SEQ ID NO:2 (plant homeobox domain); and a domain having at least 80% sequence identity with amino acids 606-674 of SEQ ID NO:2 (bromodomain).
- In some embodiments, the DNA hybridizes as described above and includes a nucleotide sequence encoding at least one of the following: amino acids 6-109 of SEQ ID NO:2 (Sp100-like domain) or amino acids 6-109 of SEQ ID NO:2 with one or more, e.g., 5, 10, 15 or 20 conservative amino acid substitutions therein; amino acids 454-532 of SEQ ID NO:2 (SAND domain) or amino acids 454-532 of SEQ ID NO:2 with one or more, e.g., 5, 10, 15 or 20, conservative amino acid substitutions therein; amino acids 537-577 of SEQ ID NO:2 (plant homeobox domain) or amino acids 537-577 of SEQ ID NO:2 with one or more, e.g., 5, 10, 15 or 20, conservative amino acid substitutions therein; and amino acids 606-674 of SEQ ID NO:2 (bromodomain) or amino acids 606-674 of SEQ ID NO:2 with one or more, 5, 10, 15 or 20, conservative amino acid substitutions therein.
- In some embodiments, the isolated DNA hybridizes as described above, and also includes a nucleotide sequence encoding all of the following: amino acids 6-109 of SEQ ID NO:2 (Sp100-like domain) or amino acids 6-109 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; amino acids 454-532 of SEQ ID NO:2 (SAND domain) or amino acids 454-532 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; amino acids 537-577 of SEQ ID NO:2 (plant homeobox domain) or amino acids 537-577 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; and amino acids 606-674 of SEQ ID NO:2 (bromodomain) or amino acids 606-674 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein.
- In some embodiments, the isolated DNA contains a nucleotide sequence that encodes a polypeptide whose amino acid sequence is the sequence set forth as SEQ ID NO:2 or the sequence set forth as SEQ ID NO:2, with one or more, e.g., 5, 10, 15 or 20 conservative amino acid substitutions therein.
- In some embodiments, the isolated DNA hybridizes as described above and also includes a nucleotide sequence encoding an Sp110 inhibitor polypeptide containing: amino acids 6-109 of SEQ ID NO:2 (Sp100-like domain) or amino acids 6-109 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; amino acids 537-577 of SEQ ID NO:2 (plant homeobox domain) or amino acids 537-577 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; and amino acids 606-674 of SEQ ID NO:2 (bromodomain) or amino acids 606-674 of SEQ ID NO:2 with one or more conservative amino acid substitutions therein; wherein the polypeptide does not contain a SAND domain.
- In some embodiments, the isolated DNA contains a nucleotide sequence (Sp110 splice variant) that encodes the amino acid sequence set forth as SEQ ID NO:5, or the sequence set forth as SEQ ID NO:5 with one or more, e.g., 5, 10, 15 or 20, conservative amino acid substitutions therein.
- The invention also features a vector containing any of the DNAs described above, and a host cell containing the vector. In the vector, the DNA can be operably linked to one or more expression control sequences.
- The invention also features a substantially pure polypeptide encoded by any of the DNAs described above. In addition, the invention includes a substantially pure polypeptide (an inhibitor of Sp110 activity) containing an Sp110 Sp100-like domain, an Sp110 SAND domain, an Sp110 plant homeobox domain, and an Sp110 bromodomain, wherein the sequence of amino acids 110 to 453 of SEQ ID NO:2 is not present. In some embodiments, this polypeptide includes a membrane transport moiety, i.e., a moiety that allows the polypeptide to enter a cell. Exemplary membrane transport moieties are an internalization peptide sequence derived from Antennapedia and an HIV tat peptide.
- The invention also features antibodies that bind specifically to the Sp110 polypeptide. The antibodies can be labeled.
- The invention also features a screening method for identifying a compound that inhibits Sp110 dimerization. The method, which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound; and detecting a decrease in Sp110 dimerization in the presence of the candidate compound, as compared to Sp110 dimerization in the absence of the candidate compound.
- The invention also features a screening method for identifying a compound that enhances or promotes Sp110 dimerization. The method, which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound; and detecting an increase in Sp110 dimerization in the presence of the candidate compound, as compared to Sp110 dimerization in the absence of the candidate compound.
- The invention also features a screening method for identifying a polypeptide that dimerizes with Sp110 to form an inactive heterodimer. The method includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate polypeptide, thereby forming a test mixture; providing a gene expression system comprising a reporter gene operably linked to an Sp110-responsive expression control sequence; contacting the test mixture with the gene expression system; and detecting a decrease in reporter gene expression level in the presence of the test mixture, as compared to gene expression level in the presence of the Sp110 polypeptide sample solution. The gene expression system can be in a living cell, e.g., a transformed host cell. Alternatively, the gene expression system can be in vitro, i.e., acellular.
- The invention also features a screening method for identifying a polypeptide that dimerizes with Sp110 to form a constitutively active or hyperactive heterodimer. The method includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate polypeptide, thereby forming a test mixture; providing a gene expression system comprising a reporter gene operably linked to an Sp110-responsive expression control sequence; contacting the test mixture with the gene expression system (which can be cellular or acellular); and detecting a constitutive activity or an increase in reporter gene expression level in the presence of the test mixture, as compared to gene expression level in the presence of the Sp110 polypeptide sample solution.
- The invention also features a screening method for identifying a compound or polypeptide that inhibits Sp110 binding to a nuclear hormone receptor. The method, which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound; adding to the sample solution a nuclear hormone receptor; and detecting a decrease in Sp110 binding to the nuclear hormone receptor in the presence of the candidate compound, as compared to Sp110 binding to the nuclear hormone receptor in the absence of the candidate compound.
- The invention also features a screening method for identifying a compound or polypeptide that enhances Sp110 binding to a nuclear hormone receptor. The method, which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound; adding to the sample solution a nuclear hormone receptor; and detecting an increase in Sp110 binding to the nuclear hormone receptor in the presence of the candidate compound, as compared to Sp110 binding to the nuclear hormone receptor in the absence of the candidate compound.
- The invention also features a screening method for identifying a compound or polypeptide that inhibits the binding of an Sp110 dimer to an Sp110-binding nucleotide sequence. The method, which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound or polypeptide; adding to the sample solution an Sp110-binding nucleotide sequence; and detecting a decrease in Sp110 binding to the Sp110-binding nucleotide sequence in the presence of the candidate compound, as compared to Sp110 binding to the Sp110-binding nucleotide sequence in the absence of the candidate compound.
- The invention also features a screening method for identifying a compound or polypeptide that enhances or promotes the binding of an Sp110 dimer to an Sp110-binding nucleotide sequence. The method, which can be in vitro, includes: providing an Sp110 polypeptide sample solution; adding to the sample solution a candidate compound or polypeptide; adding to the sample solution an Sp110-binding nucleotide sequence; and detecting an increase in Sp110 binding to the Sp110-binding nucleotide sequence in the presence of the candidate compound, as compared to Sp110 binding to the Sp110-binding nucleotide sequence in the absence of the candidate compound.
- The invention also features a method for diagnosing primary biliary cirrhosis (PBC) in a human patient. The method includes: providing a substantially pure Sp110 polypeptide; providing a serum sample from the patient; contacting Sp110 polypeptide with the serum sample; and detecting specific binding of an antibody in the serum with the Sp110 polypeptide as an indication of PBC.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present application, including definitions, will control. All publications, patents and other references mentioned herein are incorporated by reference.
- Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. The materials, methods and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the detailed description and from the claims.
- FIG. 1 is the nucleotide sequence of a full-length, human Sp110 cDNA (SEQ ID NO:1)
- FIG. 2 is a comparison of the deduced amino acid sequences of Sp110 (SEQ ID NO:2) and Sp140 (SEQ ID NO:3). Shaded portions of the sequences indicate the Sp100-like domain, the SAND domain, the plant homeobox domain (PHD), and the bromodomain. Conserved cysteine/histidine residues within the PHD are marked with asterisks. A dashed box encloses a predicted nuclear localization sequence, and a solid box encloses the LXXLL-type nuclear hormone receptor interaction domain. The sequence of the interferon-inducible protein nuclear phosphoprotein 72 begins at amino acid-241 (met) and ends at amino acid 605 (leu), which are indicated by arrows.
- FIG. 3 is the nucleotide sequence of the full-length, human Sp110 cDNA (SEQ ID NO:1) and the deduced amino acid sequence (reading frame c) of the Sp110 polypeptide (SEQ ID NO:2).
- FIG. 4 is the nucleotide sequence of a human Sp110 splice variant cDNA (Sp110b) (SEQ ID NO:4) and the deduced amino acid sequence (reading frame c) of the Sp110b polypeptide (SEQ ID NO:5).
- FIG. 5 is a schematic diagram comparing the domain structures of human Sp110, Sp140 and Sp100b. Also shown is the percent identity of the Sp110 domains, as compared to the corresponding domains in Sp140 and Sp100b.
- The full-length, naturally-occurring, human Sp110 polypeptide includes an, Sp110-like domain (amino acids 6-109 of SEQ ID NO:2), a SAND domain (amino acids 454-532 of SEQ ID NO:2), a plant homeobox domain (PHD) (amino acids 537-577 of SEQ ID NO:2), and a bromodomain (amino acids 606-674 of SEQ ID NO:2). The full-length Sp110 functions as an activator of gene transcription. Sp110 also functions as a nuclear hormone receptor co-activator. Some embodiments of the invention include all of the domains in a single Sp110 polypeptide. In other embodiments, however, one or more of the domains is modified or absent.
- The Sp100-like domain in the N-terminal portion of Sp110 has a potential helical motif, which can mediate homodimerization. (Seeler et al.,Proc. Natl. Acad. Sci. USA 95:7316-7321, 1998). It is predicted that the Sp100-like domain in Sp110 functions in protein binding interactions, e.g., dimerization, with Sp140 or Sp100 to form a heterodimer, or dimerization with a second Sp110 polypeptide to form a homodimer. Therefore, a polypeptide that contains an Sp110 Sp100-like domain (or derivative thereof), but does not contain an activating domain, can be used in a cell to form inactive dimers comprising Sp140, Sp100 or Sp110. Such formation of inactive dimers reduces the availability of endogenous Sp140, Sp100 or Sp110 monomers for formation of active (transcription-activating or transcription-inhibiting) dimers, thereby reducing Sp140, Sp100, or Sp110 activity in the cell.
- The Sp110 polypeptide is predicted to contain an activation domain located in the region between the Sp100-like domain and the SAND domain, i.e., in the region between amino acids 109 and 454 of SEQ ID NO:2. In some embodiments of the invention, a polypeptide containing this region or a derivative thereof is used to enhance or promote Sp110 activity.
- Sp110 contains a SAND domain, variations of which are found in Sp100, Sp140, AIRE-1 (Nagamine et al.,Nature Genetics 17:393-397, 1997), nuclear phosphoprotein 72, and DEAF-1 (Gross et al., EMBO J. 15:1961-1970, 1996). It is predicted that the Sp110 SAND domain is a DNA-binding domain (Gibson et al., Trends Biochem Sci. 23:242-244, 1998). In some embodiments of the invention, a polypeptide that contains a SAND domain (or derivative thereof), but lacks an activating domain, is employed as an inhibitor of Sp110 activity in a cell, e.g., a cell cultured in vitro. An example is an Sp110 polypeptide lacking the region extending from approximately amino acid 110 to amino acid 453 in SEQ ID NO:2. Such a polypeptide inhibits Sp110 activity because the SAND domain occupies some or all of the Sp110 binding sites, thereby blocking access of active Sp110 molecules to the binding sites. In some embodiments, a membrane transport moiety, e.g., the internalization peptide sequence derived from Antennapedia (Bonfanti et al., Cancer Res. 57:1442-1446) or an HIV tat peptide (U.S. Pat. No. 5,652,122) is conjugated to the SAND domain to facilitate entry of the SAND domain into living cells. In other embodiments, the carrier moiety is a polypeptide fused to the SAND domain or polypeptide containing the SAND domain, e.g., at the amino terminus of the SAND domain-containing polypeptide.
- The full-length Sp110 polypeptide contains a plant homeobox domain (PHD). This is a cysteine-rich region that spans 50-80 amino acid residues and contains the motif Cys4-His-Cys3 (Aasland et al., Trends Biochem. Sci. 20:56-59, 1995). This motif is found in many proteins that are involved in chromatin-mediated control of gene transcription. It is predicted that the Sp110 PHD functions in protein-protein or protein-DNA interactions.
- The full-length Sp110 polypeptide contains a bromodomain. It is predicted that the Sp110 bromodomain functions catalytically in acetylation of histones. The bromodomain is an α helical motif found in many proteins involved in the regulation of gene transcription (Jeanmougin et al.,Trends Biochem. Sci. 22:151-153, 1997). In general, the bromodomain is found in transcription factors that have catalytic domains. For example, SW12/SNF2 has a DNA-dependent ATPase domain (Laurent et al., Genes Dev. 7:583-591, 1993), TAFII250 (Dickstein et al., Cell 84:781-790, 1996) and TIF1α (Fraser et al., J. Biol. Chem. 273:16199-16204, 1998) have kinase domains, and GCN5 has a histone acetyl-transferase (HAT) domain (Brownwell et al., Cell 84:843-851, 1996). The original description of the bromodomain reported a conserved motif spanning approximately 60 amino acid residues and containing two a helices (Haynes et al., Nucl. Acids Res. 20;2603, 1992). Subsequently it has been suggested that the bromodomain spans 110 amino acid residues and contains two additional a helices (Le Douarin et al., EMBO J. 15:6701-6715, 1996). The four predicted a helices were designated Z, A, B, and C. The Sp110 bromodomain of SEQ ID NO:2 includes the A, B, and C helices but lacks the Z helix. Some Sp1110 splice variants may have a Z helix.
- Sp110 polypeptides, and fragments and derivatives thereof, can be obtained by any suitable method. For example, Sp110 polypeptides can be produced using conventional recombinant DNA technology, as described in the Examples below. Guidance and information concerning methods and materials for production of polypeptides using recombinant DNA technology can be found in numerous treatises and reference manuals. See, e.g., Sambrook et al, 1989, Molecular Cloning—A Laboratory Manual, 2nd Ed., Cold Spring Harbor Press; Ausubel et al. (eds.), 1994, Current Protocols in Molecular Biology, John Wiley & Sons, Inc.; Innis et al. (eds.), 1990 PCR Protocols, Academic Press.
- Alternatively, Sp110 polypeptides or fragments thereof can be obtained directly by chemical synthesis, e.g., using a commercial peptide synthesizer according to vendor's instructions. Methods and materials for chemical synthesis of polypeptides are well known in the art. See, e.g., Merrifield, 1963, “Solid Phase Synthesis,” J. Am. Chem. Soc. 83:21492154.
- Percent identity between amino acid sequences referred to herein is determined using the BLAST 2.0 program, which is available to the public at http://www.ncbi.nlm.nih.gov/BLAST. Sequence comparison is performed using an ungapped alignment and using the default parameters (Blossom 62 matrix, gap existence cost of 11, per residue gap cost of 1, and a lambda ratio of 0.85). The mathematical algorithm used in BLAST programs is described in Altschul et al., 1997, Nucleic Acids Research 25:3389-3402.
- As used herein “isolated DNA” means DNA that has been separated from DNA that flanks the DNA in the genome of the organism in the which the DNA naturally occurs. The term therefore includes a recombinant DNA incorporated into a vector, e.g., a cloning vector or an expression vector. The term also includes a molecule such as a cDNA, a genomic fragment, a fragment produced by PCR, or a restriction fragment. The term also includes a recombinant nucleotide sequence that is part of a hybrid gene construct, i.e., a gene construct encoding a fusion protein.
- As used herein, “high stringency” means the following: hybridization at 42° C. in the presence of 50% formamide; a first wash at 65° C. with 2×SSC containing 1% SDS; followed by a second wash at 65° C. with 0.1×SSC.
- As used herein, “substantially pure polypeptide” means a polypeptide separated from components that naturally accompany it. For example, a polypeptide is substantially pure when it is at least 80%, by weight, free from the proteins and other organic molecules with which it is naturally associated. Purity can be measured by any suitable method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. A chemically synthesized polypeptide or a recombinant polypeptide produced in a cell type other than the cell type in which it naturally occurs is, by definition, substantially free from components that naturally accompany it.
- As used herein, “conservative amino acid substitution” means a substitution within an amino acid family. Families of amino acid residues are recognized in the art and are based on physical and chemical properties of the amino acid side chains. Families include the following: amino acids with basic side chains (e.g. lysine, arginine, and histidine); amino acids with acidic side chains (e.g., aspartic acid and glutamic acid); amino acids with uncharged polar side chains (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine); amino acids with nonpolar side chains (e.g. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan); amino acids with branched side chains (e.g., threonine, valine, and isoleucine); and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine). An amino acid can belong to more than one family.
- A full-length Sp110 polypeptide, Sp110 polypeptide fragments containing individual Sp110 domains, or other antigenic Sp110 fragments, can be used to produce Sp110-specific antibodies. An example of an Sp110 fragment that can be used to elicit Sp110-specific antibodies is a polypeptide consisting of amino acids 219-235 of SEQ ID NO:2. The Sp110 specific antibodies can be readily obtained, without undue experimentation, through application of conventional techniques.
- In view of its production by cells involved in host defense, i.e., leukocytes, and its induction by interferon (IFN) and cytokines, Sp110 appears to play a role in inhibiting viral replication and facilitating differentiation of cells, e.g., myeloid cells, and activation of cells involved in host defense. For example, an Sp110 polypeptide can be used therapeutically to treat myeloid malignancies by virtue of its ability to promote myeloid cell differentiation. In addition, the nuclear body, of which Sp110 is a structural component, is disrupted in various human disorders, including acute promyelocytic leukemia and viral infections. Therefore, in some embodiments of the invention, an Sp110 polypeptide (or derivative thereof) is introduced into a cell in vitro or in a mammal to enhance cellular defense mechanisms. In other embodiments, Sp110 is administered therapeutically to treat inflammation or to achieve alteration in lipid profiles.
- A preformed Sp110 polypeptide can be introduced into a cell using conventional techniques for transporting proteins into intact cells, e.g., by fusing the polypeptide to the internalization peptide sequence derived from Antenntapedia (Bonfanti et al.,Cancer Res. 57:1442-1446) or to an HIV tat peptide (U.S. Pat. No. 5,652,122). Alternatively, the Sp110 polypeptide can be expressed in the cell following introduction of an Sp110-encoding DNA, e.g., in a conventional expression vector, according to the invention. In some embodiments, Sp140 is concurrently introduced into the cell, or co-expressed in the cell, so that the Sp140 can recruit the Sp110 into nuclear bodies.
- The biological activities of Sp110 include co-activation of nuclear hormone receptors, e.g., retinoic acid receptors (RARs), RXRs, LXR, FXR, peroxisome proliferator-activated receptors (PPARs), including PPARα and PPARγ, glucocorticoid receptors, estrogen receptors, progesterone receptors, androgen receptors, and orphan nuclear hormone receptors. Nuclear hormone receptors mediate signal transduction in various cellular responses. Sp110 appears to enhance expression of nuclear hormone-responsive genes by binding to a nucleotide sequence adjacent to the nuclear hormone response element and directly or indirectly enhancing gene expression. Activities of RARs and RXRs are important in cellular differentiation. Activities of PPARα and PPARγ are important in fatty acid metabolism and inflammation. Activities of FXR and LXR are important for cholesterol metabolism.
- Where increased co-activation of an Sp110-responsive nuclear hormone receptor is needed, e.g., to enhance PPARα-mediated inhibition of the inflammatory response in smooth muscle cells or endothelial cells, an Sp110 polypeptide can be supplied in a therapeutic method. Similarly, in cardiac myocytes, Sp110 may augment PPARα's effect on lipid metabolism, potentially attenuating cardiac hypertrophy. Moreover, in adipocytes Sp110 may alter PPARγ regulation of lipid storage, potentially treating obesity.
- Sometimes a nuclear hormone receptor-mediated response needs to be limited or reduced therapeutically. For example, an Sp110 derivative can be used to inhibit FXR receptors, thereby enhancing conversion of cholesterol to bile acids. In another example, Sp110 is used to block estrogen receptors in treatment of estrogen responsive tumors. The invention includes inhibitors of Sp110 activity, screening methods for identifying inhibitors of Sp110 activity, and methods of inhibiting Sp110 activity in, cells in vitro or in a mammal
- Inhibition of Sp110 activity can be accomplished through approaches including the following: a polypeptide that dimerizes with endogenous Sp110 polypeptides to form an inactive dimer; a small molecule (MW=1000 Da or less) that interferes with Sp110 dimerization; a polypeptide that occupies Sp110 binding sites (nucleotide sequences) in DNA without causing transcriptional activation; and a small molecule that interferes with Sp110-nuclear hormone receptor interactions.
- An example of a polypeptide predicted to dimerize with endogenous Sp110 polypeptides to form an inactive dimer is a polypeptide that includes amino acids 1-453 of the Sp110 sequence fused to amino acids 533-689 of the Sp110 sequence (amino acids 1-453 of SEQ ID NO:2 fused to amino acids 533-689 of SEQ ID NO:2). Such a polypeptide includes the entire Sp110 amino acid sequence except the Sp110 SAND domain, which is predicted to be required for recognizing and binding to Sp110 binding sites in DNA, but not required for Sp110 dimerization.
- An example of a polypeptide predicted to recognize and occupy Sp110 binding sites (nucleotide sequences) in DNA without causing transcriptional activation is an Sp110 SAND domain or fragment thereof.
- Polypeptides and other molecules, e.g., small molecules, that inhibit or promote Sp110 activity can be identified by screening methods provided by the invention. The type of screening method employed will depend on the type of inhibition mechanism chosen. One general approach is based on Sp110 dimerization, which is predicted to be necessary for Sp110 biological activity. One variation on this approach is to provide a molecule that interferes with Sp110 dimerization. Another variation on this approach is to provide a polypeptide that dimerizes with endogenous Sp110 polypeptides to form an inactive dimer. A second general approach is to provide a molecule that binds to (blocks) a site on the Sp110 polypeptide that interacts with nuclear hormone receptors. A third general approach is to interfere with binding of active Sp110 dimers to Sp110-binding DNA sequences in the genome. One variation on this approach is to provide a molecule, e.g., a polypeptide, that binds to (blocks) Sp110-binding DNA sequences. Another variation on this approach is to provide an oigonucleotide based on an Sp110-binding DNA sequence in the genome. The oligonucleotide binds to (blocks) the DNA-binding site(s) on the Sp110 dimer.
- Primary biliary cirrhosis (PBC) is an autoimmune disease that predominantly affects intrahepatic bile ducts. As with many other autoimmune diseases, the vast majority of patients with PBC are women and the etiology of this disorder is unknown. The natural history of PBC is one of slowly progressive cholestasis with the development of cirrhosis and death unless the patient undergoes liver transplantation. Disease progression in an individual patient, however, is highly variable and a pre-symptomatic phase may last longer than 20 years (Springer et al.,Am. J. Gastroenterol. 94:47-53,1999 and Mahl et al., J. Hepatol. 20:707-713, 1994). Because of the variable course of patients with PBC and the availability of novel treatments for this disease, it is important to identify prognostic factors that may distinguish those patients with mild disease (who may not require treatment) from those with a more aggressive, rapidly progressive, illness.
- The invention provides methods for identifying and characterizing novel autoantibody markers of disease state and prognosis in PBC patients. Serum samples from PBC patients are tested for the presence of antibodies that react with Sp110. Various types of methods for detecting and quantifying such antibody-antigen reactions are known and can be employed.
- In some embodiments of the invention, PBC-related autoantibodies are detected and characterized in methods such as conventional immunoblotting (Western) techniques, wherein an Sp110 polypeptide (or Sp110 polypeptide fragment) is employed as an antigen. Typically, the Sp110 polypeptide is subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted (transferred) onto a suitable membrane, e.g., nitrocellulose, where the Sp110 antigen is immobilized. Sera from PBC patients are diluted as necessary and contacted with the Sp110 antigen-bearing membrane under suitable conditions for specific binding of the immobilized antigen to an anti-Sp110 antigen, if one is present. After suitable washing steps, bound antibody is detected.
- Detection of bound antibody can be accomplished by any suitable method. For example, labeled protein A, which binds to IgG with high specificity and high affinity, can be used. The protein A can be labeled in any of various ways. Useful types of label include a conjugated calorimetric enzyme, e.g., horseradish peroxidase, a conjugated fluorochrome, e.g., FITC, or a radioactive atom, e.g.,125I. Immunoblot assay results can be quantitated, for example, by incorporating internal standards and a suitable optical scanning device. Preferably, suitable positive and negative controls are employed in testing patient sera. In addition to Sp110, other nuclear body components such as Sp100, Sp140 polypeptides can be tested simultaneously, e.g., on the same immunoblot membrane.
- In some embodiments of the invention, PBC-related autoantibodies are detected and quantitated using techniques designed for rapid, high-volume screening, e.g., microtiter plate ELISA techniques. Such techniques are known in the art and can be employed in practicing the present invention without undue experimentation.
- The invention is farther illustrated by the following experimental examples. The examples are provided for illustrative purposes only, and are not to be construed as limiting the scope or content of the invention in any way.
- A nucleotide sequence in the EST database that encodes a polypeptide homologous to the N-terminal portions of Sp100 and Sp140 was obtained from the IMAGE consortium (accession number AA431918). This material proved unsuitable to prepare probes for screening a cDNA library because it was highly contaminated with unrelated cDNAs. Accordingly, two oligonucleotides were synthesized based upon the sequence of the EST clone (5′-TTGAATTCATGGAAGAGGCTCTTTTTCAG-3′ (SEQ ID NO:10) and 5′-TTGAATTCCTTCTGCTAGGCCAGTTGG-3′ (SEQ ID NO:11)) and the polymerase chain reaction (PCR) was used to synthesize a fragment of the cDNA. The PCR product was radiolabeled and used to screen a λGT10 cDNA library prepared from human spleen (Clontech, Palo Alto, Calif.). Six cDNA clones from among approximately one million bacteriophages hybridized with the radiolabeled probe and were isolated by plaque purification. Bacteriophage growth, DNA isolation, and subcloning into pUC19 were performed using standard procedures (Sambrook et al, 1989, Molecular Cloning—A Laboratory Manual, 2nd Ed., Cold Spring Harbor Press, 1989). The nucleotide sequence of the full-length cDNA was determined by the dideoxy chain termination method (Sanger et al., Science 214:1205-1210, 1981). The sequences of the six clones, when assembled, revealed the sequence of the fall length Sp110 cDNA (FIG. 1).
- The cDNA encoding Sp110 was 2,337 base pairs long, with an open reading frame from nucleotides 78 to 2144 encoding a protein containing 689 amino acids (FIGS. 1 and 3). The start codon was preceded by an in-frame stop codon, indicating that this is a full-length cDNA. The amino acid residues at 241 to 605 of Sp110 were essentially identical to
residues 1 to 365 of a previously reported polypeptide designated nuclear phosphoprotein 72 (Kadereit et al., J. Biol. Chem. 268: 24432-24441, 1993). In this region, the amino acid sequence of Sp110 differed from that of nuclear phosphoprotein 72 at amino acid 580 (I-M). - The N-terminal portion of Sp110, between amino acid residues 6 and 159 was 49% identical to the N-terminal portions of both Sp100 (Szostecki et al.,J. Immunol. 145:4338-4347, 1990) and Sp140 (Bloch et al., J. Biol. Chem. 46:29198-29204, 1996). A second region of homology between Sp110 and both Sp100b and Sp140 was present between
amino acid residues 452 and 532. In this region, Sp110 was 53% identical to Sp100b (Dent et al., Blood 88:1423-1436, 1996) and 49% identical to Sp140. This portion of Sp100b and Sp140 was previously designated a SAND domain (Gibson et al., Trends Biochem Sci. 23:242-244, 1998). Sp110 amino acid residues 537 to 577 spanned a plant homeobox domain (Aasland et al., Trends Biochem. Sci. 20:56-59, 1995), and amino acid residues 606 to 674 contained the A, B, and C helices of a bromodomain (Jeanmougin et al., Trends Biochem Sci. 22:151-153, 1997). The plant homeobox domain and bromodomain of Sp110 were 71% and 54% identical to the corresponding regions in Sp140. In addition, these portions of Sp110 were 56% and 46% identical to the corresponding regions in murine TIF1α. - The level of Sp110 mRNA in human tissues was determined by hybridizing membranes containing 2.5 μg of poly(A)+-selected RNA from human tissues (multiple tissue Northern blots, Clontech Laboratories, Palo Alto, Calif.) with a 32P-radiolabeled 1.4 kb XbaI restriction fragment of the Sp110 cDNA. The human tissues represented on the membranes were spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. The membranes were washed under stringent conditions and exposed to autoradiographic film for one hour. To confirm the presence of poly(A)+-selected RNA in each lane, the membranes were hybridized with a 32P-radiolabeled β-actin cDNA probe. The membranes were washed under stringent conditions and exposed to autoradiography film for 30 minutes.
- High levels of Sp110 mRNA were detected in human peripheral blood leukocytes and spleen. In contrast, lower levels of Sp110 mRNA were observed in thymus, prostate, testis, ovary, small intestine, and colon. In addition, low levels of Sp110 mRNA were observed in human heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas.
- To investigate the expression of Sp110 in cells of the monocyte/granulocyte lineage, RNA was prepared from the myeloid precursor cell lines HL60 and NB4 (HL60 cells are available from the American Type Culture Collection, Manassas, Va.). RNA was extracted from these cell lines using the guanidinium isothiocyanate-cesium chloride method (Sambrook et al., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989). The HL60 cells were maintained in RPMI supplemented with 10% fetal calf serum, L-glutamine (2 mM), penicillin (200 units/ml), and streptomycin (200 mg/ml). RNA was fractionated in formaldehyde-agarose gels (5 μg/lane) and equal loading of RNA was confirmed by staining 28S and 18S ribosomal RNA with ethidium bromide. RNA was transferred to nylon membranes and the membranes were hybridized with the radiolabeled XbaI restriction fragment of the Sp110 cDNA or the EcoRI/BamHI restriction fragment of the cDNA encoding human Sp100 (Bloch et al.,J. Biol. Chem. 46:29198-29204, 1996). Membranes were washed and analyzed by autoradiography. Low levels of Sp110 mRNA were detected in both NB4 cells and HL60 cells.
- To examine the effect of cellular differentiation on Sp110 mRNA, NB4 cells were treated for 48 hours with all trans retinoic acid (ATRA) (1 μM). Following this treatment, the level of Sp110 mRNA was increased in NB4 cells, which indicates that differentiation of NB4 cells is associated with increased expression of Sp110. To examine the effect of IFN-γ treatment on Sp110 mRNA levels, HL60 cells were treated with IFN-γ (200 units/ml) for 48 hours. A marked increase in Sp110 mRNA was observed. These results demonstrated that, as with Sp100, PML, and Sp140, IFN-γ-treatment enhances expression of Sp110.
- Sp110 expression was also examined in human coronary artery smooth muscle cells (hCASMCs) and human umbilical vein endothelial, cells (HUVECs) following exposure to IFNα (200 u/ml). Expression of Sp110 mRNA was induced within 4 hours and reached a maximum level between 8 and 24 hours. Similar results were obtained after treating hCASMCs or HUVECs with IFNγ or IL-1β and TNFα. Sp110 gene expression was also markedly induced in hearts of mice treated with endotoxin, suggesting that inflammatory mediators increase Sp110 mRNA levels in cardiac myocytes.
- The observation that Sp110 was expressed in human leukocytes and cytokine-treated human vascular cells suggested that Sp110 is present in cells that have important roles in the pathogenesis of atherosclerosis.
- To study the cellular location of Sp110, antiserum directed against a recombinant fragment of Sp110 (amino acid residues 219 to 324) was generated in rats, and an adenovirus vector encoding Sp110 (Ad.Sp110) was prepared.
- To construct an E1-deleted, recombinant adenovirus vector containing Sp110, the cDNA encoding Sp110 was cloned into the NotI and BamHI sites of pAd.RSV4, which contained the Rous sarcoma virus long-terminal repeat promoter and the SV40 polyadenylation signal. The plasmid containing Sp110 was co-transfected into 2093 cells with pSM17. Homologous recombination between the two plasmids resulted in an adenovirus (Ad.Sp110) that contained Sp110 sequences in place of E1 sequences. Recombinant viruses in a plaque were amplified in 293 cells, and a high-titer stock was prepared. The 293 cells were grown in low glucose (1 g/L)-DMEM supplemented with 10% horse serum. The absence of replication-competent adenovirus in the viral stock was confirmed by the failure of Ad.Sp110 to produce cytopathic changes in A549 lung carcinoma cells. In addition, PCR failed to amplify a DNA fragment corresponding to the E1 region of adenovirus using oligonucleotides and the Ad.Sp110 stock. An adenovirus vector containing the cDNA encoding Sp140 was described previously in (Bloch, et al., Mol. Cell. Biol. 19:4423-4430,1999).
- To produce antibodies directed against Sp110, three male Sprague-Dawley rats were immunized with recombinant protein containing amino acid residues 219-435 of Sp110 fused to glutathione-S-transferase (GST). The plasmid encoding this portion of Sp110 was prepared by ligating a BstYI/EcoRV restriction fragment of the cDNA encoding Sp110 into the BamHI/SmaI sites of pGEX (Pharmacia Biotech, Inc., Piscataway, N.J.). The plasmid was used to transformE. coli, and expression of the fusion protein was induced by treatment with isopropyl-1-thio-β-D-galactopyranoside. The fusion protein was purified from E. coli proteins as described in (Smith et al., Gene 67:31-40, 1988). Primary immunizations of three rats was performed using 50 μg of purified protein emulsified in complete Freund's adjuvant for each animal. Two subsequent booster injections consisting of 50 μg of protein were given at two-week intervals.
- The rat anti-Sp110 antiserum reacted with Sp110 in extracts prepared from Ad.Sp110-infected HEp-2 cells, but not with Sp140 in extracts prepared from Ad.Sp140-infected HEp-2 cells or with Sp100, which is normally expressed in HEp-2 cells. In contrast, rat anti-Sp140 antiserum, previously prepared against amino acid residues 131-391 of Sp140 (Bloch et al.,J. Biol. Chem. 46:29198-29204, 1996), reacted with Sp140, but not with Sp110 or Sp100. These results demonstrated that the rat anti-Sp110 antiserum was specific for Sp110.
- To investigate the cellular location of Sp110, rat anti-Sp110 antibodies were used to stain NB4 cells before and after treatment with RA. Anti-Sp110 antiserum stained nuclear bodies in NB4 cells that were treated for 48 hours with ATRA (1 μM), but did not react with untreated NB4 cells.
- To determine the location of Sp110 with respect to the PML/Sp100 nuclear body, NB4 cells were treated with ATRA and stained with rat anti-Sp110 antiserum and human serum containing antibodies directed against Sp100. Sp110 co-localized with Sp100 in nuclear bodies.
- To further investigate the cellular location of Sp110, adenovirus-mediated gene transfer was used to express Sp1110 in human cell lines in which it is not normally expressed. At a multiplicity of infection (MOI) of 25 viruses per cell, approximately 25% of HEp-2 cells expressed levels of Sp110 that were detectable by indirect immunofluorescence. Surprisingly, Sp110 did not localize to nuclear bodies in these cells, but instead appeared to produce a granular nuclear staining pattern with prominent staining near the nuclear membrane. Cytoplasmic staining was also observed in a few cells. The contrasting results obtained using the leukocyte cell line NB4 and Ad.Sp110-infected HEp-2 cells can be reconciled with the present result if Sp140, another leukocyte-specific nuclear body component, recruits Sp110 to the nuclear body. HEp-2 cells were infected with both Ad.Sp140, at an MOI of 50, and Ad.Sp110, at an MOI of 25. At an MOI of 50, essentially all of the HEp-2 cells expressed detectable Sp140 within nuclear bodies. In cells infected with Ad.Sp140 alone, anti-Sp110 antiserum did not stain nuclear bodies, confirming that anti-Sp110 antiserum did not cross-react with Sp140. In cells infected with both Sp110 and Sp140, Sp110 localized to nuclear bodies and co-localized with Sp100-containing nuclear bodies. These results demonstrated that Sp140 enhances localization of Sp110 to the nuclear body.
- The amino acid sequence motifs in Sp110, including the SAND domain, the PHD, and the bromodomain, suggested that Sp110 has a role in the regulation of gene transcription. To examine the potential effect of Sp110 on gene transcription, a eukaryotic expression plasmid encoding Sp110 fused to the DNA-binding domain of GAL4 (pBXG-Sp1110) was co-transfected with a CAT reporter plasmid containing five GAL4 binding sites and an SV40 enhancer region (pG5SV-BCAT) into COS cells. There was a dose-dependent increase in CAT activity in cells transfected with increasing amounts of pBXG-Sp110. These results are similar to those observed using pBXG-Sp140 and different from those obtained with pBXG-Sp100. The GAL4-Sp100 fusion protein was previously shown to inhibit CAT activity when co-transfected with the reporter plasmid (Seeler et al.Proc. Natl. Acad. Sci. USA 95:73167321, 1998; Lehming et al., Proc. Nat. Acad. Sci. USA 95:7322-7326, 1998; and Bloch, et al., Mol. Cell. Biol. 19:4423-4430, 1999). These results demonstrated that Sp110 is capable of modulating gene transcription and acts in these cells as a transcriptional activator.
- Experiments were also performed to determine whether Sp110 could function as a retinoic acid receptor (RAR) transcriptional co-activator. When co-transfected into COS cells with a reporter gene containing three copies of the RARα response element, Sp110 significantly enhanced ATRA-induced expression of the reporter gene. Similar results were observed in studies using HeLa cells instead of COS cells. The extent of reporter gene activation by Sp110 was similar to that induced by the nuclear body component PML. These results demonstrated that Sp110 can function as a co-activator of the nuclear hormone receptor RAR.
- Sp110 also acted as a co-activator of PPARα. When COS cells were co-transfected with PPARα and a reporter gene containing three copies of the PPAR response element (PPRE), Sp110 markedly enhanced agonist-induced expression of the reporter gene compared with the effect of PPARα expressed alone. Sp110 may interact with nuclear hormone receptors via an LXXLL domain. To determine whether Sp110 interacts with PPARα via the LULL domain, oligonucleotides and PCR were used to prepare a mutant Sp110 protein (Sp110m) in which two of the three leucine residues were changed, one to valine and one to alanine (LXXVA).
- Although immunoblot studies demonstrated that Sp110 and Sp110m were expressed at similar levels in transfected COS cells the Sp110 mutant activated the PPARα receptor less than wild-type Sp110. These results demonstrated that Sp110 functions as a PPARα transcriptional co-activator and indicated that the interaction between Sp110 and PPARα may involve the LXXLL nuclear hormone receptor interaction domain.
- Sp110 enhanced signal transduction through the retinoic acid receptor α (RARα) (LaMorte et al.,Proc Natl Acad Sci USA 95:4991-4996, 1998) and, in contrast to the results obtained with PPARα, expression of Sp110m with RARα also enhanced expression of the reporter gene. Similarly, both Sp110 and the Sp110 mutant enhanced signal transduction through the PPARγ receptor. These results suggested that Sp110 had an effect on RARα signaling and PPARγ signaling, perhaps through interaction with nucleotide motifs adjacent to nuclear hormone receptor response element(s). Although the examples below involved the PPARα receptor, it is predicted that similar results will be achieved with other nuclear hormone receptors.
- PPARα interacted with the N-terminal portion of CBP/p300 between amino acid residues 39 and 221. To determine whether Sp110 also interacts with CBP, the mammalian two-hybrid system was used as an assay. In this assay, the GAL4 DNA-binding domain (GAL4) fused to CBP (GAL4-CBP) and a luciferase reporter gene containing GAL4 response elements were expressed in COS cells with either Sp110 fused to the herpes simplex virus VP16 activation domain (VP16-Sp110) or VP16 alone. Expression of VP16-Sp110 significantly enhanced Ga14-CBP-induced luciferase gene activity compared with VP16 alone. Thus, Sp110 interacts, either directly or indirectly, with CBP. The site of functional interaction between Sp110 and CBP was mapped more specifically to amino acid residues 271-720 of CBP. The Sp110-CBP functional interaction domain is therefore distinct from the PPARα-CBP interaction domain.
- To identify the portion of Sp110 that functionally interacts with CBP, the N-terminal or C-terminal portions of Sp110 were fused to VP16 and expressed in COS cells together with GAL4CBP and a reporter gene. The C-terminal portion, which contained the PHD and the bromodomain, enhanced GAL4-CBP-induced expression of the reporter gene, but the N-terminal portion, which contained the Sp100-like region, did not. As described below, studies can be carried out to further delineate the domains that mediate functional interaction between Sp110 and CBP and to test whether Sp110 interacts with CBP directly.
- Sp110 does not contain motifs, such as acetyltransferase (as in CBP/p300) or kinase domains (as in TIF1α), that are known to activate gene transcription. To identify the portion of Sp110 that enhances reporter gene expression, DNA segments encoding fragments of Sp110 fused to GAL4 were expressed with a reporter gene in COS cells. Neither the N-terminal (Sp100-like domain), nor the C-terminal (PHD/bromodomain) portions of Sp110 increased expression of the reporter gene. In contrast, fusion proteins containing the middle portion of the protein (putative activation domain and SAND domain) increased reporter gene expression. The mechanism by which Sp110 enhances PPARα-mediated gene transcription can be investigated, as described below, by identifying proteins that interact with the activation domain and SAND domain.
- This experiment tests the possibility that Sp110 enhances expression of a reporter gene under the control of the native promoter region of CPTI, a gene that is regulated by PPARα. Co-transfection studies are performed in COS cells using a luciferase reporter construct that contains a CPTI gene promoter having the PPRE (AGGGAAaAGGTCA; SEQ ID NO:______). The effect of co-expression of Sp110 and PPARα on luciferase activity is compared to that of Sp110, PPARRα, or control vectors alone. An expected result is that Sp110 enhances PPARα-mediated expression of the reporter gene under the control of the CPTI promoter region.
- Sp110 may enhance luciferase expression by interacting with other regulatory elements within the CPTI promoter region. To demonstrate that the effect of Sp110 on luciferase activity requires PPARα, the effect of Sp110 on a luciferase reporter plasmid that has a mutated PPRE (AGGGAAaAccTCA; SEQ ID NO:______), is determined. If Sp110 enhances CPTI promoter-driven luciferase activity by interacting with PPARα, then an expected result is that Sp110 has no effect on expression of the reporter plasmid with the mutated PPRE.
- The fibroblast cell line 3T3-L1 can be induced to differentiate into cells that resemble white adipocytes. These cells normally express low levels of enzymes involved in mitochondrial fatty acid oxidation. To test the possibility that Sp110 enhances PPARα-mediated upregulation of mitochondrial fatty acid oxidation gene expression, Sp110 is overexptessed in 3T3-L1 cells using an adenovirus vector (Ad.Sp110). An unrelated protein, green fluorescent protein (GFP), is expressed as a control using a second adenovirus vector (Ad.GFP). 3T3-L1 cells will be infected with Ad.Sp110 or Ad.GFP at a virus MOI sufficient to produce infection of more than 90% of the cells. The cells are then incubated in medium containing insulin, 3-isobutyl-1-methylxanthine (IBMX), and dexamethasone to induce differentiation (Cao et al.,Genes Dev., 5:1538-1552, 1991). Immunobloting is performed to confirm successful transgene expression. RNA blot hybridization will be performed to measure the effect of Sp110 (compared with GFP) on expression of three fatty acid oxidation genes (MCAD, LCAD, and CPT-I) in the presence or absence of the PPAR(X agonist WY 14,643.
- To examine the effect of Sp110 on the rate of fatty acid oxidation, 3T3 L1 cells are infected with either Ad.Sp110 or Ad.GFP, and the rate of palmitate oxidation is determined (Gulick et al.,Proc. Natl. Acad. Sci., USA, 91:11012-11016, 1994). Seventy-two hours after infection, the cells are incubated with [14C] palmitate. The tissue culture plates contain a central well with, a piece of filter paper. After 6 hours, the 14Co2 is released from tissue culture medium by addition of 6 N HCl and 14CO2 is collected overnight by alkalinization of the filter paper with 2 N NaOH. 14CO2 is measured by scintillation counting of the filters.
- Mutations in the LXXLL domain of Sp110 impair its ability to enhance PPARα-mediated expression of a reporter gene, most probably by blocking the direct interaction between PPARα and Sp110. To investigate the importance of the LXXLL domain in enhancing PPARα mediated gene expression, an adenovirus vector encoding Sp110m (Ad.Sp110m) is tested for its ability to induce expression of MCAD, LCAD, and CPT-I and to increase fatty acid oxidation in 3T3-L1 cells. The results of these tests with Ad.Sp110m are directly compared with those obtained using Ad.Sp110.
- An expected result is that Sp110, but not GFP, enhances Wy 14,643-induced (PPARα agonist-induced) expression of genes involved in fatty acid oxidation and increase palmitate oxidation in 3T3-L1 cells. Because the effect of Sp110 on PPARα is expected to require direct interaction between the two proteins, Sp110 is expected to be more effective than Sp110m at producing these changes. If Sp110 and Sp110m are equally effective at inducing fatty acid oxidation, the putative LXXLL interaction domain in Sp110 is deemed non-crucial for this effect. In that event, studies to define alternative interaction sites between PPARα and Sp110 could be carried out.
- 3T3-L1 cells express relatively low levels of PPARα. In fact, these levels may be too low to detect any effect of Sp110 on genes normally regulated by PPARα. Thus, if there appears to be no enhancement of expression of genes involved in fatty acid oxidation following infection with Ad.Sp110, the studies are performed using an adenovirus vector encoding PPARα. Successful production of PPARα is confirmed using immunoblots and a commercially available anti-PPARα antibody. 3T3-L1 cells will be infected with Ad.GFP, Ad.Sp110, Ad.PPARα, or both Ad.Sp110 and Ad.PPARα. The effect of Ad.PPARα and Ad.Sp110 (together) on the expression of fatty acid oxidation genes and palmitate oxidation rates is compared to the effect of Ad.Sp110, Ad.PPARα, and Ad.GFP alone.
- Inflammatory cytokines such as IL-1 induce expression of IL-6 and COX-2 in smooth muscle cells (SMCs). This expression can be blocked, however, if the SMCs are; treated with PPARα agonists (Staels et al.,J. Clin. Invest. 103:1489-1498, 1999). Endogenous Sp110 expression in SMCs was enhanced by treatment with inflammatory cytokines. Thus, Sp110 is expected to enhance PPARα-mediated inhibition of the inflammatory response in SMCs.
- Forty-eight hours after human coronary artery SMCs (hCASMCs) are infected with Ad.Sp110, they are treated with recombinant human IL-1 and Wy14,643. The amount of IL-6 released by SMCs is measured by radioimmunoassay. To confirm that the effect of Ad.Sp110 on PPARα-mediated inhibition of IL-6 production is not a result of the Ad vector alone, control cells are infected, in parallel, with Ad.GFP at the same MOI as used for Ad.Sp110. Cells are treated with IL-1 and Wy14,643 and IL-6 production are measured as described above.
- Because Sp110 also is expected to augment the ability of PPARα to inhibit COX-2 gene expression, SMCs are infected with Ad.Sp110 and subsequently treated with IL-I as described above. The cells are treated with increasing amounts of the PPARα agonist Wy14,643 and the concentration of COX-1 and COX-2 protein will be measured using immunoblot techniques. Parallel experiments are conducted with Ad.GFP as a control.
- While the concentration of COX-1 is expected to be unaffected either by expression of Sp110 or by treatment with IL-1 or WY14,643, the concentration of COX-2 is expected to change. A lower concentration of COX-2 at each dose of WY14,643 in Ad.Sp110-infected cells (relative to Ad.GFP-infected cells), would suggest that Sp110 augments the ability of PPARα to inhibit COX-2 expression in SMCs in response to IL-I.
- The biological function of Sp110 can be assessed in numerous ways, including studies in which it is overexpressed (as can be done to investigate its role in PPARα-mediated signal transduction) and studies in which oligopeptides are used as inhibitors (as can be done to inhibit the ligand-dependent interaction between PPARα and Sp110).
- Two complementary oligonucleotides encoding a peptide that spans seven amino acids on either side of the LXXLL domain of Sp110 are synthesized and ligated, in frame, to GAL4 in a eukaryotic expression plasmid (pGAL-LXXL). To demonstrate that the GAL4-oligopeptide fusion protein acts an, inhibitor, this expression plasmid are co-transfected into COS cells with plasmids encoding PPARα, Sp110, and a reporter gene construct in which the reporter is driven by PPRE. As a control, cells are transfected in parallel with a plasmid encoding pGAL alone. The use of GAL4 as a fusion partner facilitates nuclear localization of the oligopeptide. In addition, successful production of the GAL4-oligopeptide fusion protein in transfection assays is confirmed by immunoblotting with anti-GAL4 antibodies. Expression of the GAL4-oligopeptide in COS cells is expected to block agonist-specific, Sp110-mediated, activation of PPARα.
- To examine the effect of inhibiting the interaction between PPARα and Sp110 in hCASMCs, an adenovirus vector encoding GAL4-LXXLL and a control virus encoding GAL4 fused to the same amino acid residues in random rearrangement are prepared. hCASMCs are treated with IL-1 and subsequently infected with either Ad.GAL4-LXXLL or the control adenovirus vector. The production of IL-6 and the induction of COX-2 are assayed as described above.
- Treatment of hCASMCs with cytokines induces expression of Sp110. Overexpression of an oligopeptide corresponding to the LXXLL domain in Sp110 would be expected to block Sp110 coactivation of PPARα-mediated gene expression. Thus, the oligopeptide is expected to enhance the cytokine-mediated induction of IL-6 and COX-2.
- Mutations in the putative nuclear hormone receptor interaction domain of Sp110 inhibit the ability of Sp110 to enhance PPARα-mediated transcriptional activity. These results suggest that the LXXLL domain in Sp110 interacts with PPARα. It is possible, however, that other portions of Sp110 also mediate its interaction with PPARα. Mammalian two-hybrid assays are used to identify the portions of Sp110 and PPARα that mediate functional interaction between these two proteins.
- To identify the portion(s) of Sp110 that mediate interaction with PPARα, DNA molecules encoding portions of Sp110 (the Sp100-like region, putative activation domain, SAND domain, LXXLL domain, PHD, and bromodomain, individually and in combination) are ligated into the eukaryotic expression vector pVP16 in-frame with the HSV VP16 activation domain. Each of the resulting plasmids are co-transfected into COS cells with a second plasmid encoding PPARα and a reporter gene containing a PPRE. Successful, production of each fragment of Sp110 is confirmed using immunoblots and an antibody directed against VP16. The ability of each VP16-Sp110 fusion protein to enhance reporter gene expression in the presence of PPARα and agonist provides evidence for a functional interaction between a given Sp110 portion and PPARα. Control experiments are conducted to rule out the possibility that VP16-Sp110 fusion proteins activate the reporter gene in the absence of PPARα. In addition, the inability of PPARα and VP16-Sp110 fusion proteins to activate reporter gene expression from a plasmid that lacks the PPRE will be confirmed.
- To identify portions of PPARα that mediate interaction with Sp110, DNA molecules encoding portions of PPARα will be ligated into a eukaryotic expression plasmid in-frame with GAL4. The plasmids will be co-transfected with a plasmid encoding Sp110 fused to VP16 and a reporter gene with an upstream GAL4 response element. Gene expression mediated by GAL4-PPARα-fragment and Sp110 will be compared to that mediated by the same GAL4-PPARα-fragment and control plasmid. The ability of VP16-Sp110 to enhance GAL4-PPARα-fragment-induced reporter gene expression will be evidence of an interaction between Sp110 and a PPARα fragment.
- These studies will identify the portions of Sp110 and PPARα that mediate functional interaction between the two proteins. Among others, the interaction domains should include the LXXLL domain of Sp110 and the ligand-binding “
activation function 2” (AF2) portion of PPARα. - Sp110 is predicted to interact directly with PPARα. A GST-Sp110 fusion protein is prepared and tested in vitro for interaction with35S-radiolabeled PPARA. DNA encoding Sp110 is ligated in-frame with DNA encoding glutathione-S-transferase (GST) in the prokaryotic expression plasmid pGEX so as to encode a GST-Sp110 fusion protein. The recombinant fusion protein is expressed in E. coli, affinity-purified, and immobilized on Sepharose beads. DNA encoding PPARα are used to prepare 35S-radiolabeled protein by in vitro transcription and translation and will be incubated with Sepharose-GST-Sp110 (or Sepharose-GST alone) in the presence and absence of PPARα agonist. Bound and radiolabeled PPARα is eluted from Sepharose-GST-Sp110 (or Sepharose-GST) by boiling in SDS/PAGE sample buffer, and the eluant will be fractionated by SDS/PAGE.
- Retention of PPARα on Sepharose-GST-Sp110, but not on control Sepharose-GST, provides evidence for a direct interaction between PPARα and Sp110. In addition, if PPARα is retained on Sepharose-GST-Sp110 in the presence, but not in the absence, of PPARα agonist then the direct interaction between PPARα and Sp110 requires the presence of nuclear hormone receptor agonist.
- A mammalian two-hybrid assay was used to demonstrate a functional interaction between the PHD/bromodomain of Sp110 and amino acids 271-720 of CBP. Sp110 may also interact directly with CBP. To determine whether or not it does, a GST-CBP(271-720) fusion protein will be prepared (as described above for Sp110) and exposed to35S-radiolabeled Sp110. An 35S-radiolabeled nuclear body component, PML, can serve as a positive control for interaction with CBP, as PML interacts with CBP in this portion of the protein (Doucas et al., Proc. Natl. Acad. Sci. USA, 96:2627-2632, 1999). If CBP interacts directly with Sp110, then a Sepharose-GST-CBP (271-720) fusion protein, but not Sepharose-GST alone, would be expected to retain radiolabeled Sp110.
- CBP has been described as a “platform” protein because it interacts with many other proteins. Among the proteins that interact with CBP at amino acid residues 271-720 are: RXR, STAT2, CREB, JUN, MYYB, ELK1, SREBP, and SAP1A (Giles et al.,Trends Genetics, 14:178-183, 1998). Instead of a direct interaction between Sp110 and CBP, at least one other protein may mediate the functional interaction between these two proteins. If a direct interaction between Sp10 and CBP cannot be demonstrated using GST pulldown experiments, then the mammalian two-hybrid system will be used to further delineate the site in CBP that mediates functional interaction with Sp110. Two approaches can then be taken to identify the protein(s) that link CBP and Sp110. A candidate gene approach will involve obtaining cDNAs encoding proteins that are known to interact with the identified portion of CBP. Proteins encoded by these cDNAs will be tested for interaction with Sp110 using a combination of GST pull-down and mammalian two-hybrid assays. If none of the candidate genes interacts with Sp110, then the yeast two-hybrid system will be used to identify cDNAs encoding proteins that link CBP and Sp110. A DNA fragment encoding the PHD/bromodomain of Sp110, and a DNA fragment encoding the portion of CBP that mediates functional interaction with Sp110, will each be used to screen a human leukocyte cDNA library. Complementary DNAs encoding interacting proteins will be divided into groups that interact with Sp110, CBP, or both. Verification of “true” protein-protein interactions are then performed, as described below.
- Sp110 appears to enhance expression of nuclear hormone responsive genes by binding to a nucleotide sequence adjacent to the nuclear hormone response element and directly or indirectly enhancing gene expression. The sand domain of Sp110 may mediate DNA binding. By interacting directly with DNA, Sp110 may enhance gene expression independent of the LXXLL motif. A GAL4-Sp110 fusion protein is capable of activating expression of a reporter gene driven by the GAL4 response element, and neither the N-terminal, which contains the Sp100-like domain, nor the C-terminal, which contains the LXXLL/PHD/bromodomain) of Sp110 are required to mediate enhanced expression of the reporter gene. The middle portion of Sp110 contains a SAND domain, an amino acid sequence motif that has been observed in several proteins that regulate gene transcription.
- To identify and characterize cDNAs encoding proteins that interact with Sp110's activation domain, a DNA fragment encoding that domain will be used as “bait” in the yeast two-hybrid assay. The DNA fragment are ligated into plasmid pGBKT7 (Clontech) and transferred into yeast with a leukocyte cDNA library prepared in pGADT7. The transformed yeast will be screened for the ability to grow on His− medium and colonies that grow on this medium will be tested for α-galactosidase (α-gal) activity. Complementary DNAs are recovered from positive yeast clones and re-tested for interaction with bait by a second round of transformation in yeast. If numerous positive clones are obtained, they will be sorted into groups on the basis of size and restriction sites, and representative clones will be tested for interaction with an unrelated bait fusion protein. Clones encoding proteins that specifically interact with the Sp110 activation domain, but not the unrelated protein, will be sequenced and further characterized
- In vitro co-immunoprecipitation, in vivo co-immunoprecipitation and mammalian two-hybrid assays will be used to confirm functional interactions between Sp110 and proteins produced by cDNAs identified using yeast two-hybrid. These studies identify cDNAs encoding proteins that interact with the activation domain of Sp110. The identity of these proteins will provide additional information regarding the mechanism by which Sp110 functions as a nuclear hormone receptor co-activator.
- In an alternative approach, proteins that interact with the activation domain are identified by purifying interacting proteins from cell extracts using recombinant Sp110 protein linked to Sepharose beads. Purified proteins will be fractionated in polyacrylamide gels, transferred to IMMOBILON™ filters, and subjected to amino acid microsequencing. These techniques have been used previously to purify and identify the predominant autoantigen in patients with autoimmune sensorineural hearing loss (Bloch et al.,Archives of Otolaryngology-Head and Neck Surgery 121:1167-1171, 1995).
- This study demonstrates that antibodies directed against nuclear body components Sp140 and Sp110 identify a subset of PBC patients with a variant form, e.g., a relatively mild form, of PBC. Serum from a well-defined cohort of 370 PBC patients are tested by immunoblot for antibodies directed against Sp110 and Sp140.
- Adenovirus vectors containing cDNAs encoding Sp140, Sp110, and Sp100 produce high levels of protein in human 293 cells. Aliquots of cell lysates sufficient to screen 5,000 sera for each of these antigens are prepared. Cell lysates are boiled in loading buffer, fractionated in an 8% polyacrylamide gel, and transferred to nitrocellulose membranes. A miniblot apparatus is applied to the membrane. This permits screening of 20 sera on each membrane. As a preliminary screen, patient serum is diluted 1:200 in PBS containing 5% nonfat dry milk and incubated for one hour at room temperature with the nitrocellulose. Membranes are washed three times with PBS and incubated with horseradish peroxidase (HRP) conjugated-protein A diluted 1:5000 in PBS. Filters are washed three times in PBS, incubated with chemiluminescence reagent, and then exposed to film. If a serum sample appears to contain antibodies directed against the recombinant protein, then a second immunoblot is performed. This second membrane has two lanes, one containing protein from 293 cells infected with adenovirus encoding the nuclear body protein, and the second containing protein from cells infected with the control adenovirus. The presence of an appropriate size band in the former lane, but not the latter, is taken as confirmation of the presence of autoantibodies directed against the nuclear body component. This second immunoblot excludes false-positive results that may be secondary to human antibodies reacting with 293 cell proteins or adenovirus proteins produced in these cells.
- The diagnosis of PBC in the 370-patient cohort is established based on the presence of abnormal liver function tests, AMA (titer≧1:20) and liver biopsy compatible with PBC. The findings on liver biopsy are classified into four stages (portal hepatitis, periportal hepatitis, septal fibrosis and/or bridging necrosis, cirrhosis). The cohort includes 234 women and 36 men. The date of presentation was defined as the first documentation of abnormal liver enzymes. The median age at presentation is 52 years (range 24-81). The median length of follow-up is nine years (range 1-27). Symptoms of PBC in these patients include pruritis, jaundice, portosystemic encephalopathy, bleeding varices, edema and ascites. Endpoints of the study are liver transplantation, death from liver disease and death from other causes.
- To demonstrate that antibodies directed against Sp110 and Sp140 identify a subset of patients with a mild form of PBC, serum from these patients are screened for the presence of antibodies using immunoblot as described above. For the purpose of this study, mild disease is defined as liver biopsy at presentation showing stage I or II disease and survival during the course of the study without requiring liver transplantation.
- A number of embodiments of the invention have been described. Nevertheless, it is understood that various modifications may be made without departing from the spirit and scope of the invention. Other embodiments are within the scope of the claims that follow.
Claims (26)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/333,227 US7087717B2 (en) | 2000-07-24 | 2001-07-24 | Sp110, a polypeptide component of the nuclear body |
US11/472,065 US20060234289A1 (en) | 2000-07-24 | 2006-06-21 | Sp110, a polypeptide component of the nuclear body |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22030500P | 2000-07-24 | 2000-07-24 | |
PCT/US2001/023248 WO2002008383A2 (en) | 2000-07-24 | 2001-07-24 | Sp110, a polypeptide component of the nuclear body |
US10/333,227 US7087717B2 (en) | 2000-07-24 | 2001-07-24 | Sp110, a polypeptide component of the nuclear body |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/472,065 Division US20060234289A1 (en) | 2000-07-24 | 2006-06-21 | Sp110, a polypeptide component of the nuclear body |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030216548A1 true US20030216548A1 (en) | 2003-11-20 |
US7087717B2 US7087717B2 (en) | 2006-08-08 |
Family
ID=22823010
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/333,227 Expired - Fee Related US7087717B2 (en) | 2000-07-24 | 2001-07-24 | Sp110, a polypeptide component of the nuclear body |
US11/472,065 Abandoned US20060234289A1 (en) | 2000-07-24 | 2006-06-21 | Sp110, a polypeptide component of the nuclear body |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/472,065 Abandoned US20060234289A1 (en) | 2000-07-24 | 2006-06-21 | Sp110, a polypeptide component of the nuclear body |
Country Status (2)
Country | Link |
---|---|
US (2) | US7087717B2 (en) |
WO (1) | WO2002008383A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087717B2 (en) * | 2000-07-24 | 2006-08-08 | The General Hospital Corporation | Sp110, a polypeptide component of the nuclear body |
WO2011044125A1 (en) * | 2009-10-05 | 2011-04-14 | Ambergen, Inc. | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens |
WO2012069525A1 (en) * | 2010-11-25 | 2012-05-31 | Glaxo Group Limited | Inhibitors of sp140 and their use in therapy |
WO2012055878A3 (en) * | 2010-10-27 | 2012-06-21 | Glaxo Group Limited | Method of treatment |
CN102621313A (en) * | 2011-01-28 | 2012-08-01 | 上海科新生物技术股份有限公司 | Colloidal gold chromatography anti-Sp100 antibody detection test paper and preparation method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2405447C2 (en) | 2005-10-24 | 2010-12-10 | Тайхо Фармасьютикал Ко., Лтд. | METHOD OF PREDICTING EFFICIENCY OF RAR-α AGONIST |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4194997A (en) * | 1975-05-05 | 1980-03-25 | Edler Folke J | Sulfite spent liquor-urea formaldehyde resin adhesive product |
US4247433A (en) * | 1978-06-10 | 1981-01-27 | Th. Goldschmidt Ag | Process for the preparation of thermosettable urea-formaldehyde resins and method for use thereof |
US4410685A (en) * | 1982-09-10 | 1983-10-18 | Borden, Inc. | Hydrolytically stable urea-formaldehyde resins and process for manufacturing them |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US6183988B1 (en) * | 1996-10-02 | 2001-02-06 | The General Hospital Corporation | Leukocyte-specific protein and gene, and methods of use thereof |
US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
US20040171012A1 (en) * | 2001-06-01 | 2004-09-02 | Henry Yue | Nucleic acid-associated proteins |
US20040171823A1 (en) * | 2003-01-14 | 2004-09-02 | Nadler Steven G. | Polynucleotides and polypeptides associated with the NF-kappaB pathway |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087717B2 (en) * | 2000-07-24 | 2006-08-08 | The General Hospital Corporation | Sp110, a polypeptide component of the nuclear body |
-
2001
- 2001-07-24 US US10/333,227 patent/US7087717B2/en not_active Expired - Fee Related
- 2001-07-24 WO PCT/US2001/023248 patent/WO2002008383A2/en active Application Filing
-
2006
- 2006-06-21 US US11/472,065 patent/US20060234289A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4194997A (en) * | 1975-05-05 | 1980-03-25 | Edler Folke J | Sulfite spent liquor-urea formaldehyde resin adhesive product |
US4247433A (en) * | 1978-06-10 | 1981-01-27 | Th. Goldschmidt Ag | Process for the preparation of thermosettable urea-formaldehyde resins and method for use thereof |
US4410685A (en) * | 1982-09-10 | 1983-10-18 | Borden, Inc. | Hydrolytically stable urea-formaldehyde resins and process for manufacturing them |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US6183988B1 (en) * | 1996-10-02 | 2001-02-06 | The General Hospital Corporation | Leukocyte-specific protein and gene, and methods of use thereof |
US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
US20040171012A1 (en) * | 2001-06-01 | 2004-09-02 | Henry Yue | Nucleic acid-associated proteins |
US20040171823A1 (en) * | 2003-01-14 | 2004-09-02 | Nadler Steven G. | Polynucleotides and polypeptides associated with the NF-kappaB pathway |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087717B2 (en) * | 2000-07-24 | 2006-08-08 | The General Hospital Corporation | Sp110, a polypeptide component of the nuclear body |
WO2011044125A1 (en) * | 2009-10-05 | 2011-04-14 | Ambergen, Inc. | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens |
US11885802B2 (en) | 2009-10-05 | 2024-01-30 | Ambergen, Inc. | Method for diagnosing primary biliary cirrhosis (PBC) using novel autoantigens |
WO2012055878A3 (en) * | 2010-10-27 | 2012-06-21 | Glaxo Group Limited | Method of treatment |
WO2012069525A1 (en) * | 2010-11-25 | 2012-05-31 | Glaxo Group Limited | Inhibitors of sp140 and their use in therapy |
US9018184B2 (en) | 2010-11-25 | 2015-04-28 | Glaxo Group Limited | Inhibitors of SP140 and their use in therapy |
CN102621313A (en) * | 2011-01-28 | 2012-08-01 | 上海科新生物技术股份有限公司 | Colloidal gold chromatography anti-Sp100 antibody detection test paper and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US20060234289A1 (en) | 2006-10-19 |
WO2002008383A3 (en) | 2003-10-02 |
WO2002008383A2 (en) | 2002-01-31 |
US7087717B2 (en) | 2006-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6159731A (en) | Daxx, a Fas-binding protein that activates JNK and apoptosis | |
US7101714B2 (en) | Molecules of the card-related protein family and uses thereof | |
US5863795A (en) | Nucleic acids that encode peptides which modulate apoptosis | |
WO1998034946A9 (en) | Daxx, a novel fas-binding protein that activates jnk and apoptosis | |
US20040053262A1 (en) | Supressor gene | |
AU3408695A (en) | Retinoblastoma protein-interacting zinc finger proteins | |
US20060234289A1 (en) | Sp110, a polypeptide component of the nuclear body | |
US6830914B2 (en) | RGS-containing molecules and uses thereof | |
JP2007527193A (en) | THAP protein as a nuclear receptor for chemokines and its role in transcriptional regulation, cell proliferation, and cell differentiation | |
US20070081987A1 (en) | Novel peptides and compositions which modulate apoptosis | |
US6476206B1 (en) | p40 protein acts as an oncogene | |
US5905146A (en) | DNA binding protein S1-3 | |
US6048702A (en) | Murine and human box-dependent myc-interacting protein (Bin1) and uses therefor | |
US6323335B1 (en) | Retinoblastoma protein-interacting zinc finger proteins | |
US6872811B1 (en) | HRPCa9 and HRPCa10 nucleic acids and polypeptides | |
US7217692B2 (en) | Complex of a human FOXC2 protein and a FOXC2-interacting protein | |
JP2005525087A (en) | GIP, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding proteins | |
US5959081A (en) | Zinc binding LIM protein S2-6 | |
US6582956B1 (en) | Tumor suppressor gene | |
WO2001038526A1 (en) | Human tnf receptor | |
JPWO2005118631A1 (en) | Novel protein complex and its use | |
US6444439B1 (en) | Cloning and characterization of a cdc15-like adaptor protein (CD2BP1) | |
US6768003B1 (en) | Nucleic acids that encode transcriptional adaptor proteins | |
EP0833924A1 (en) | Adenovirus e1a-associated protein bs69, inhibitor of e1a-transactivation | |
WO1999067269A1 (en) | Nucleic acid molecule encoding an ankyrin repeat tvl-1 protein and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENERAL HOSPITAL CORPORATION, THE, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLOCH, DONALD B.;BLOCH, KENNETH D.;REEL/FRAME:013972/0143;SIGNING DATES FROM 20030207 TO 20030214 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.) |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20180808 |